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The collagen fibers that span the periodontal ligament (PDL) connect teeth to the bone 
socket by weaving through the cementum of each tooth as well as into the alveolar bone. 
Collagen type I is the main structural component of the PDL. High rates of extracellular 
matrix (ECM) turnover are characteristic of PDL tissue. Periodontal disease (PD) afflicts 
approximately 50% of the population in the United States. PD is marked by chronic 
inflammation of the periodontium leading to PDL degradation, alveolar bone loss, and 
eventual tooth loss. There are currently no accepted methodologies to regenerate this 
collagenous PDL tissue. Thus PDL provides an excellent tissue milieu for investigating 
mechanisms of collagen processing and assembly during inflammatory states that are 
clinically relevant. SPARC, a collagen-binding protein, has been identified as a key 
factor in collagen ECM deposition. We reported that SPARC-null mice have significantly 
less total collagen, thinner collagen fibers, and reduced mechanical strength in PDL 
compared to wild type (WT) PDL. A key factor in incorporation and stabilization of 
insoluble collagen within the ECM is mediated through collagen cross-linking. 
Transglutaminases (TGs) are a family of extracellular proteins known to participate in 
collagen cross-linking activity in vitro and in vivo. Previous data implicate SPARC as a 
critical regulator of TG activity on collagen I in homeostatic PDL. Inhibition of TG 
activity in vivo was shown to reverse SPARC-dependent decreases in collagen volume 
fraction and mechanical strength of homeostatic PDL. Our data predicts SPARC 














CHAPTER 1: INTRODUCTION  
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1. Periodontal ligament collagen  
The periodontal ligament (PDL) is the collagenous tissue that anchors tooth root 
cementum into underlying alveolar bone. The principle components of the PDL are blood 
vessels, fibroblasts, and collagen fibers.  Fibroblasts, the most common cells of 
mammalian connective tissue, are the main cell type responsible for synthesizing and 
secreting extracellular matrix (ECM) and collagen to maintain the structural integrity of 
the PDL. Collagen is the most abundant protein in the human body and makes up 25% to 
35% of whole-body protein content; 90% of which is composed of collagen type I [1]. 
One of the major characteristics of PDL collagen is its exceptionally high rate of 
turnover, making the PDL an ideal tissue to investigate mechanisms of collagen assembly 
and incorporation into the ECM [2]. Fibrillar collagens, particularly types I (~75%), III 
(20%), and V (5%), are the major components of PDL providing tensile strength and 
stability [3]. Additionally, non-fibrillar collagen types IV, VI, XII, and XIV are also 
present in minor amounts within the PDL [4]. Fibrillar collagens are highly glycosylated 
and surrounded by water, hyaluronic acid, and proteoglycans which provide resistance 
against compressive forces within the periodontal ligament ECM [5]. 
Collagen type I is the most abundant type of collagen in the collagen superfamily 
(made up of 28 family members) and the main structural component of murine and 
human PDL. Type I collagen is a heterotrimeric helical molecule comprised of two α1 
chains and one α2 chain. The right-handed helix of type I collagen is approximately 300 
nm long, 1.5 nm in diameter, and has a distinct amino acid arrangement of Glycine-X-Y, 
where X and Y are frequently Proline and Hydroxyproline, respectively. Glycine is found 
at almost every third residue of collagen I, and proline makes up about 17% of type I 
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collagen. Hydroxyproline, derived from the hydroxylation of proline residues, and 
hydroxylysine, derived from lysine, are modified post-translationally by prolyl-(3,4)-
hydroxylase enzymes. Proline and hydroxyproline act to stabilize the super coils of the 
triple helices of individual polypeptide strands of the collagen molecule in a favorable 
entropic and stable thermal state [6]. The complete absence of prolyl hydroxylation in 
animal models results in lethality [7].   
The synthesis of the collagen molecule (Fig. 1) begins with mRNA transcription of 
genes associated with specific collagen alpha peptide (1, 2, or 3) formation (34 COL 
genes). Once the mRNA exits the fibroblast nucleus it associates with the ribosomal 
subunits in the cytoplasm to begin the process of translation. The newly formed trimeric 
protein is known as the pre-pro-peptide with N- and C-terminal propeptides. The C-
terminal propeptide is implicated in collagen alpha chain recognition, that takes place in 
the endoplasmic reticulum, and in collagen I solubility [8]. The N-propeptide of collagen 
I, particularly encoded in exon 2 of the COL1A1 gene, has also been proposed to 
contribute to collagen I solubility. However, the precise functional role of the N-terminal 
propeptide is poorly understood and thus is a central subject of examination in Section 1 
of Chapters 3 and 4. The signal sequences on the N- and C-terminal propeptides are 
recognized by signal recognition particles on the endoplasmic reticulum (ER), which are 
responsible for directing the pre-pro-peptide into the ER for post-translational 
modification where it is now known as pre-pro-collagen. The pre-pro-collagen molecule 
is modified by the addition of hydroxyl groups to the amino acids proline and lysine by 











assembly.	 The	 figure	 outlines	 the	 sequential	 processes	 involved	 in	 formation	 of	 a	
mature	 collagen	 fiber.	 N-propeptide	 function	 and	 intra-molecular	 cross-linking	 of	
collagen	I	in	the	extracellular	matrix	are	investigated.		
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Both hydroxylase enzymes require ascorbic acid (vitamin C) as a cofactor and work to 
aid in cross-linking of the alpha peptides [9]. Deficiency of ascorbic acid, typically 
associated with scurvy, results in the lack of hydroxylation of prolines and lysines 
causing the formation of a loose collagen triple helix. Patients suffering from scurvy 
often develop gingival ulcerations and rapid tooth loss [10]. Hydroxylation is an 
important precursor step that allows for subsequent glycosylation to occur. Glucose or 
galactose monomers are added onto hydroxyl groups on lysines, but not prolines, during 
glycosylation. The formation of the triple alpha helical structure inside the RER, 
composed of two hydroxylated and glycosylated alpha-1 chains and one alpha-2 chain, 
are transported to the Golgi apparatus as a procollagen molecule for packaging and 
secretion. Procollagen undergoes one final post-translational modification in the Golgi 
apparatus where oligosaccharides are added prior to excretion into the extracellular space. 
Procollagen molecules are transported outside the cell with assistance from collagen-
binding proteins, which behave as chaperones to facilitate exocytosis. Collagen-binding 
proteins are critical in collagen fibril synthesis, fiber assembly, and collagen deposition 
into the ECM. Once outside the cell, the terminal N- and C- propeptides are cleaved by 
procollagen peptidase enzymes resulting in the formation of a tropocollagen molecule 
[9]. Defects in the formation of tropocollagen result in the collagenopathy Ehlers-Danlos 
syndrome. Patients with Ehlers-Danlos syndrome exhibit a wide range of oral 
manifestations including luxations of the TMJ, gingival fragility, excessive hemorrhage 
during dental procedures, early-onset periodontitis, and enamel hypoplasia [11].  
Additionally, several other disorders associated with collagen mutations manifest with 
severe oral complications (Table 1). Multiple tropocollagen molecules assemble by the 
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formation of covalent bonding facilitated by cross-linking enzymes (lysyl oxidase and 
transglutaminase) to form collagen fibrils. Multiple collagen fibrils aggregate to form 
mature collagen fibers and attach to cell surfaces through transmembrane receptors such 
as integrins and glycoproteins such as fibronectin [9].  
Individual collagen fibrils of the PDL are organized into fiber bundles, which span 
the width of the PDL and are the only non-mineralized fibers to connect two distinct hard 
tissues (tooth and bone) in the mammalian body. The terminal ends of PDL collagen 
bundles are embedded in the alveolar bone and tooth cementum and form partially 
mineralized Sharpey’s fibers [12]. Individual collagen fibrils are continuously remodeled 
by fibroblasts at a rapid rate in the PDL demonstrating a half-life of 2 – 12 days in 
various animal species [13, 14]. Tissue accessibility and high collagen turnover rate and 
content make the PDL an ideal tissue for better understanding mechanisms of collagen 
assembly, stabilization, and regeneration applicable to a variety of collagen-rich tissues.  
 
2. Degradation of fibrillar PDL collagen during PD  
Periodontal disease (PD) is a chronic inflammatory condition initiated by the 
formation of a bacterial biofilm colonizing the tooth surface and periodontal pocket (Fig. 
2). Keystone pathogens colonizing the bacterial biofilm are activated and initiate an 
immune response in the local environment. Initial influx of immune infiltrate to local site 
of inflammation is exasperated by host immune response and inability to clear immune 
cells. Chronic inflammation of PD in tissues of the periodontium (tooth, PDL, alveolar 
bone) leads to progressive degradation of PDL collagen fibers, loss of alveolar bone 
volume, and eventual tooth loss.  
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Scurvy  N/A • Halitosis 
• Ulcerative; hemorrhagic gingival tissue 
• PDL degradation 
• Premature loss of dentition [15] 
Oral Submucous 
Fibrosis 
N/A • Xerostomia 
• Oral mucosa pigmentation 
• Thinning & tightening of lips  
• Oral epithelial atrophy  
• Tongue papilla atrophy  
• Recurrent ulceration  
• Restricted soft palate  
• Shrunken uvula  




N/A  • Xerostomia 




• Dysgeusia [17] 
Sjogren’s Syndrome  N/A • Xerostomia  
• Early onset caries  
• Enlarged salivary glands [18] 
Scleroderma N/A • Xerostomia, microstomia, telangietasia  
• Gingival recession  
• Increased tongue rigidity  
• Pseudoankylosis of TMJ [19] 
• Restricted oral aperture  
• Loss of PDL integrity 
• Radiographic widening of PDL space 
• Increased risk of PD development  
• Mandibular bone resorption  





• Gorlin sign 
• Absence of inferior labial and lingual frenula 
• Gingival fragility; excessive hemorrhage during 
dental procedures 





• Dentinogenesis Imperfecta: dentin dysplasia, DEJ 
scalloping, enamel fracturing & loss, caries, 
periapical abscesses, pulp chamber obliteration, 
irregular dentinal tubules [22] 
• Class III malocclusion [23] 
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• Micrognathia   
• Glossoptosis 
• Bifid uvula  
• Cleft palate [24] 
Alport Syndrome • COL4A3/4/5/6 • Gingival overgrowth [25] 
Chondrodysplasia 
Punctata 
• COL2A1 • Enamel hypoplasia  
• Reduced dental arch length & tooth size  
• Maxillary & mandibular growth attenuation [26] 
Epidermolysis 
Bullosa  
• COL7A1 • Enamel hypoplasia  
• Ankyloglossia  
• Lingual depapillation 
• Palatal rugae & tongue atrophy  
• Intraoral ulcerations & bullae formation 
• Microstomia  
• Absence of buccal & vestibular sulci  
• Early onset caries [27] 
Knobloch Syndrome  • COL18A1 • Xanthogranuloma 
• Labial nodular lesions 
• Fibrotic frenae  
• Orthopantomograph  
• Frequent enamel fractures; exaggerated Retzius 
lines  
• Rotated incisors  
• DEJ scalloping 
• Early onset caries  
• Mulberry molars [28] 











Maintaining the integrity of the PDL collagen fibers and restoring these structures 
following disease treatment are essential for maintaining a healthy dentition [29].  
Collagenous ECM turnover occurs in homeostatic tissues through a balance of matrix 
breakdown, resorption, and remodeling. Pathological conditions characterized by 
accelerated breakdown of connective tissue, such as PD, are a failure of normal 
regulatory mechanisms. Periodontal pathogens stimulate cytokine production (IL-1β, 
TGF-β) and prostaglandins (E2) in response to a bacterial endotoxin lipopolysaccharide 
(LPS) that, in turn, induces matrix metalloproteinase (MMP) synthesis by resident 
gingival immune cells [30]. MMPs are a family of 25 proteinases capable of digesting 
macromolecules of tissue matrices including collagen. Of particular interest in the PDL is 
the collagenase group of MMPs (1, 8, 13, 18) and the gelatinase MMPs (2 and 9), which 
are the only known mammalian enzymes capable of degrading fibrillar collagens [31]. 
MMP collagen-binding domains facilitate interaction between enzyme and collagen 
substrates. MMP binding along collagen fibrils facilitates neutrophil migration, and cell 
movement on collagen via integrins, and induction of cytoskeletal rearrangement [32]. 
Inter-domain flexing occurs between collagen-binding domains of MMPs and facilitates 
bending of collagen peptide and unwinding/cleavage of triple helical collagen [33]. 
Elevated levels of MMP-2 and -9 mRNA are associated with PD severity in human 
subjects [34]. Tissue inhibitors of MMPs (TIMPs), secreted by most connective tissue 
cells and macrophages, form high-affinity, non-covalent complexes with active forms of 
MMPs to control their activity. Decreased human salivary levels of TIMP-1 mRNA are 




Figure	 2.	 Tissue	 Destruction	 in	 PD.	 Representation	 of	 bacterial	 biofilm	
colonization	into	the	oral	epithelial-tooth	interface.	As	periodontal	pocket	develops	
plaque	antigens	stimulate	neutrophil	and	monocyte	activation	to	produce	cytokines	






Recent clinical trials have utilized antibiotic cocktails with MMP inhibitory activity, 
following periodontal treatment, to restore the imbalance between MMPs and TIMPs to 
homeostatic levels [36]. While the resolution of MMP and TIMP balance in the PDL aids 
in faster resolution of local inflammatory response, it does not restore damaged/degraded 
tissues; it attenuates disease progression. Additionally, the development of antibiotic 
resistance has raised concern about long-term use of such treatments to manage the 
chronic inflammation of PD [37].  
To date, available treatment options for PD are limited (Fig. 3). Initial treatment 
begins with clearance of biofilm causing plaque and calculus through scaling and root 
planing. Loss of periodontal tissue structure from advanced, chronic PD is treated with 
surgical intervention involving gingival flap surgery and tissue and bone grafts combined 
with antibiotic therapy to attenuate further tissue loss. Long-term success rates of soft and 
hard tissue grafts have been unreported and seem to depend largely on severity of disease 
state and patient-specific confounding factors [38]. Once, PD has progressed to tooth 
loss, the only treatment to prevent further resorption of the alveolar bone is to replace the 
structure with a metal/zirconium implant. Implant placement involves direct contact of 
implant with alveolar bone without a soft tissue intermediary to absorb/distribute forces 
of mastication, which is implicated in the high 10-year failure rate of 50% [39]. 
Periodontal surgery treatments do not recover or restore PDL collagen state; similar to 
other PD therapies, surgery simply attenuates the disease state at the present stage. 
Methods of collagen regeneration are the focus of many studies aimed at restoring 





Figure 3. PD Progression & Current Therapeutic Interventions. Degradation of PDL 
collagen fibers due to PD directly leads to resorption of alveolar bone and tooth loss in 
patients. Current therapies can attenuate PD only once diagnosed. Upon diagnosis 
significant collagen composition of the PDL has already been permanently degraded. A 
better understanding of mechanisms of collagen assembly and stability in the ECM of the 















3. SPARC maintains collagen I content in the ECM of the PDL during homeostasis  
Secreted protein acidic and rich in cysteine (SPARC/osteonectin/BM-40) is a 40kDa 
collagen-binding matricellular glycoprotein whose expression is closely aligned with that 
of fibrillar collagens such as collagen type I. SPARC is most highly expressed in ECM of 
tissues during states of collagen deposition: embryonic tissues development, wound 
healing, tissue turnover, and fibrotic disease states [40]. Many cell types including 
endothelial cells [41], fibroblasts [42], pericytes [43], osteoblasts [44], and macrophages 
[45] express SPARC. SPARC plays a vital role in tissue mineralization, cell-matrix 
interactions, collagen binding, angiogenesis, and cell migration. Unlike other 
matricellular proteins such as thrombospondin and tenascin, SPARC is anti-adhesive and 
inhibits cell spreading and proliferation [46]. The single polypeptide chain of SPARC is 
composed of four domains: 1. an extracellular calcium-binding (EC) domain near the 
glutamic acid-rich region located at the amino terminus, 2. a cysteine-rich domain, 3. a 
hydrophilic region, and 4. an EF hand motif located at the carboxy terminus [47]. 
Evidence that SPARC binds fibrillar collagens I, III, and V via its EC domain in addition 
to basement membrane collagen IV, implicate SPARC in the assembly of connective 
tissue ECM as well as basement membranes [40].  
ECM collagen assembly and the activity of TGF-β1 are both influenced by SPARC 
expression. TGF-β1 is a cytokine known to stimulate the synthesis of collagen type I and 
increase SPARC expression [42]. In a reciprocal manner, addition of exogenous SPARC 
to mesangial cells in vitro, resulted in TGF-β1 induction and collagen I synthesis [48]. 
Reductions in SPARC expression, mediated by siRNA silencing, decreased TGF- β1 
expression in cultured human fibroblasts. Since TGF-β1 is considered a profibrotic 
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cytokine, the ability of SPARC to regulate TGF-β pathways implicates SPARC in 
controlling fibrotic tissue states [49].  
Examination of SPARC-null mice is highly useful in understanding ECM synthesis 
and collagen assembly. The SPARC-null mouse is well established and utilized in a 
number of experimental studies. The global abrogation of SPARC expression in 
transgenic mice most frequently utilized is created by the deletion of exon 4 in the 
SPARC gene [50]. Upon gross examination, SPARC-null mice appear phenotypically 
similar to their WT counterparts with the exception of a curly tail [51]. Abrogation of 
SPARC in mice does not affect body weight or lifespan. However, these mice develop 
premature cataracts, as early as 1.5 months of age, due to deficient lens epithelial cell 
formation of basement membranes [50]. A number of other abnormalities detected in 
SPARC-null mice are manifested in ECM structure and function, implicating the 
important role of SPARC in collagen assembly and deposition.    
A lack of SPARC expression has been shown to diminish mature collagen 
accumulation in the ECM of many connective tissues including PDL [40, 52]. SPARC-
null mice exhibit decreased total collagen I content in the PDL in addition to other tissues 
(tendon, dermis, cardiac). Likewise, there is diminished deposition of fibrotic collagen in 
PDL tissues in the absence of SPARC. Studies have shown a correlation between 
increased levels of SPARC expression and stimulated increases in collagen deposition 
and assembly into the ECM [53]. Increases in soluble collagen in SPARC-null mice also 
suggest that incorporation of collagen into insoluble collagen fibrils is not efficient in the 
absence of SPARC [54]. Studies performed in fibroblasts have suggested that SPARC 
acts to facilitate procollagen processing by limiting procollagen association with cell 
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surface receptors [55, 56]. The SPARC binding site on collagen overlaps with that of the 
collagen receptor Discoidin Domain Receptors (DDR) 1 and 2 [57]. Hence, SPARC 
bound to collagen I might limit binding to cell surface DDR2 and therefore decrease 
signaling initiated via DDR2 as well as possibly allowing for more efficient incorporation 
of collagen into insoluble ECM. Speculatively, increased interaction of soluble collagen 
with DDR2 in the absence of SPARC might tether procollagen at cell surfaces leading to 
increased turnover of collagen at the cell surface at the expense of collagen deposition 
into the ECM.    
Previous studies from our laboratory have examined the function of SPARC in 
collagen homeostasis specifically to maintain healthy murine PDL from development 
through adulthood (summarized in Table 2). Expression patterns of SPARC were 
distinguishable in murine PDL at all age points (1, 4, 6, and >18 months), with robust 
increased expression in developing 1 month PDL and aging >18 month PDL; age points 
which both correlate with increased ECM turnover and remodeling. Homeostatic adult 
PDL displayed baseline expression levels of SPARC [58]. Results of SPARC expression 
in PDL correspond to elevated levels of expression during development, ECM 
remodeling, and wound healing reported in other tissues (dermal, cardiac, tendon) [55, 
59-62]. Fibroblast cell population was decreased in young, 1-month PDL in the absence 
of SPARC but remained constant in WT PDL. It was postulated that fibroblasts in the 
absence of SPARC had delayed migration from dental follicle to alveolar bone compared 




Table 2. Summary of Homeostatic PDL Alterations in the Absence of SPARC [58] 
 Murine PDL Age 
Characteristic Genotype 1 month 4 months 6 months >18 months 
SPARC expression WT High Low Absent High 
Fibroblast population WT 80% 80% 88% 98% 
SPARC-null 70% 85% 86% 92% 
Interstitial space WT Low Low Low Moderate 
SPARC-null Moderate Moderate High Absent 
Collagen I content WT 75% 80% 75% 78% 
SPARC-null 67% 64% 72% 50% 
Thick fiber content WT 60% 64% 71% 65% 













However, increasing age points restored fibroblast cell population in SPARC-null PDL 
until >18 months when cell population decreased again. Total collagen I content as well 
as thick fiber content in SPARC-null PDL was significantly decreased compared to WT 
PDL at all age points but was most robust at 1- and >18-month age points. The increased 
number of fibroblast cell nuclei at 1- and >18- months might indicate a compensatory 
mechanism in an attempt for the PDL to restore the exacerbated loss of collagen fibers at 
these time points. Additionally, these time points correlate to the highest levels of 
SPARC expression in the PDL. The authors propose the absence of SPARC gives rise to 
increased collagen turnover at fibroblast cell surfaces resulting in inefficient collagen 
incorporation to insoluble ECM, decreased total collagen I content, and smaller fibers in 
homeostatic murine PDL at various age points [58].        
 
4. Function of SPARC in mineralized tissue  
At one time SPARC was thought to be expressed specifically in mineralized tissues 
(thus the name osteonectin) but was subsequently demonstrated to have a much wider 
expression pattern in both mineralized and non-mineralized tissues (summarized in Table 
3) [63]. The protein component of the pre-mineralized bone matrix (osteoid) is composed 
mainly of collagen type I (94%) and a number of noncollagenous proteins. The 
mechanical properties of bone are largely attributed to the mineral composition of the 
osteoid in the form of hydroxyapatite (HA) - a complex of calcium and phosphate - that 
mineralizes the collagenous matrix. Generally, calcified bone is comprised of ~ 70% HA, 
25% matrix, and 5% water [64]. SPARC contains both a collagen-binding domain and an 
HA binding region [63].  
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Table 3. Activities attributed to SPARC in mineralized and non-mineralized cells 






































































In the osteoid, SPARC has been proposed to bind collagen and HA crystals and release 
calcium ions perhaps enhancing mineralization of the collagen matrix in bones [52]. The 
function of SPARC in mineralized tissues both during homeostasis and disease has yet to 
be fully defined, however a significant amount of insight into SPARC activity in 
mineralized tissues has emanated from analysis of SPARC-null mice and identified 
mutations in the gene encoding SPARC in human disease (Fig. 4). 
SPARC is encoded by a single gene, on chromosome 5 (5q31 – q33) that generates a 
secreted, monomeric, glycosylated polypeptide. SPARC has four defined domains: 1) an 
N-terminal low-affinity, high capacity, calcium-binding domain that contains the mineral 
binding region, 2) a Cysteine-rich domain, 3) a hydrophilic region, and 4) an extracellular 
Ca2+ (EC) domain with an E-F hand motif at the C-terminus that encompasses the 
collagen binding domain. The helix-loop-helix structure (EF hand motif) is a domain 
characteristic of some calcium-binding proteins and is composed of two alpha helices and 
one short loop region [77]. SPARC is a glycoprotein shown to undergo differential 
glycosylation dependent upon tissue-specific expression. Importantly, the glycosylated 
form of SPARC, expressed in bone, binds collagen with higher affinity than the form 
found in platelets [78].  
SPARC is secreted by osteoblasts in bone during bone formation [44]. The collagen-
binding domain of SPARC, at the C-terminus is separated from the hydroxyapatite-
binding site at the N-terminal region. The separation of these two interacting domains has 






procollagen	 processing	 4)	 mineral	 incorporation,	 and	 5)	 collagen	 cross-linking.	
Steps	shown	with	yellow	boxes	are	processes	regulated	by	SPARC	that	potentially	




Similar to patterns of SPARC expression in other tissues, levels of SPARC are high in 
immature bone and are associated with mineralization of collagen whereas a decrease in 
SPARC expression is observed in mature bone homeostasis [44]. Notably, SPARC is 
expressed at high levels in osseous tissue with high turnover such as in active osteoblasts 
and bone marrow progenitor cells, odontoblasts (dentin-forming cells), periodontal 
ligament fibroblasts, hypertrophic chondrocytes, and osteoid [44, 58, 63, 78, 79]. SPARC 
is not only synthesized by osteoblasts, but also by endothelial cells and fibroblasts present 
in mineralized tissues [41].  
Initial characterization of SPARC-null mice indicated no overt phenotypic differences 
in skeletal development in the absence of SPARC [80]. However, subsequent studies 
have revealed significant differences in the bone phenotype in SPARC-null versus WT 
mice. SPARC-null mice have a curly tail, demonstrate decreases in bone mineral density, 
develop low-turnover osteopenia at an early age, and exhibit slight decreases in the length 
of femur long bones [65]. Despite these phenotypic abnormalities, the absence of SPARC 
expression does not significantly influence lifespan, reproduction, or overall body weight. 
Similar to connective tissue, skeletal defects in SPARC-null mice were most pronounced 
under conditions of active bone remodeling. For example, SPARC-null mice develop 
accelerated intervertebral disc degeneration [74, 81]. In addition, whereas WT mice 
exhibit significant increases in bone mineral density in response to bone-anabolic 
parathyroid hormone treatment, SPARC-null mice do not [82]. 
The first reported skeletal phenotype in SPARC-null mice was early onset osteopenia 
[83]. Osteopenia is characterized by decreased bone mineral density and is considered by 
some clinicians to be a precursor to osteoporosis. The osteopenia indicative of SPARC-
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null mice became progressively worse with age. At 11 weeks, radiographic differences in 
trabecular bone density of femurs were detected in SPARC-null versus WT mice. By 17 
weeks of age, differences in bone density impacted femur bone strength as SPARC-null 
bones demonstrated reduced biomechanical properties versus WT bones measured by the 
3-point bending test. Whereas WT bones gained strength from 11 to 17 weeks, the bones 
of SPARC-null mice did not as evidenced by lower measured maximum load (N), 
maximum displacement (mm), and stiffness (N/mm) [83]. SPARC-null mice have 
decreased numbers of osteoblasts and osteoclasts and an ~50% reduction in bone-
formation rates [83]. SPARC-null tibia 17 weeks had 50% less trabecular bone volume 
compared to WT tibia as indicated by decreases in trabecular number and increases in 
trabecular spacing quantitated by histomorphometric measurements. Trabecular bone 
volume of SPARC-null tibia decreased further with age (36 weeks) to 70% less than WT 
trabecular bone volume [83]. Frequently, decreased bone formation in both the trabecular 
and cortical bone compartments is characteristic of osteopenia. Interestingly, in SPARC-
null mice, osteopenia was primarily observed in trabecular bone where bone resorption 
was greater than bone formation leading to a decrease in bone mass that was compounded 
over time. Trabecular bone is frequently more affected in deficiencies characterized by 
reduced bone mineral density and SPARC expression was more readily detected in 
extracts from trabecular versus cortical bone [52].  
The osteonectin 3’ UTR has two identified haplotypes associated with bone mineral 
density (BMD): A and B. Haplotype A is found at a higher frequency in severe 
osteoporotic patients demonstrating decreased BMD, whereas haplotype B is more 
commonly associated with healthy controls and higher BMD levels. A single nucleotide 
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polymorphism (SNP1599) in the 3’ untranslated region of SPARC has been shown to 
associate with reduced bone volume in patients with idiopathic osteoporosis [84]. 
Specifically variants SNP1599G found in haplotype A and 1599C found in haplotype B 
were compared. To discern whether SNP1599C/G influenced the expression of SPARC 
in vivo, mice carrying SNP1599C/G were genetically engineered [85]. Mice carrying the 
SNP1599G variant deposited less mineralized matrix, less cortical bone area, less 
trabecular bone volume with age, and decreased overall bone formation rates in 
comparison to mice carrying SNP1599C variant and to control mice. Increased cortical 
bone area in response to intermittent PTH treatment was less in mice with SNPS1599G 
than that of 1599C variant mice. SNP1599G introduced a novel miR-433 binding site in 
the 3’UTR of SPARC [85]. The 3’ UTR of many mRNAs is known to have regulatory 
effects on gene expression through modulation of mRNA stability, targeting, and/or 
translation. Accordingly, SNPs within the SPARC 3’UTR might influence synthesis of 
SPARC and contribute to variations in expression patterns among individuals. During 
osteoblast differentiation, the expression of miR-433 decreases and inhibitors of miR-433 
promote osteoblast differentiation [85]. Hence miR-433 is predicted to act as an inhibitor 
of osteoblast differentiation. SNP1599G osteoblasts were shown to have defects in 
differentiation both in vitro and in vivo. SPARC expression levels were decreased by the 
inclusion of SNP1599G, presumably through inhibition mediated by miR-433 [85].  
Closer examination of SPARC-null bones has revealed specific alterations in collagen 
structure, mineral composition, and apatite crystallite morphology in comparison to WT 
bones [67]. In line with a low bone turnover rate in the absence of SPARC, higher 
mineral contents and increases in crystal size were found in SPARC-null bones. In 
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addition, infrared microspectroscopic measurements of SPARC-null cortical bone 
collected from three dimensions of tibia revealed decreased rates of bone formation 
despite the absence of differences in overall cortical thickness versus WT bones [67]. 
Hence, SPARC-dependent defects in trabecular bone formation were also observed in 
cortical bone. Likely, elevated mineral content and highly cross linked matrix generated 
by slow turnover in the absence of SPARC maintained cortical bone thickness whereas 
overt decreases in trabecular bone density were more easily detected. Nonetheless, 
mechanical properties of cortical bone were weakened in SPARC-null mice demonstrated 
by increased bone fragility despite normal cortical area [83]. Synthesis of mRNA 
encoding collagen I subunits along with other ECM proteins associated with bone 
formation were not significantly altered in SPARC-null versus WT mice at 17 weeks of 
age [83]. Hence, although basic multicellular units (BMUs), the functional unit 
comprised of osteoblasts and osteoclasts, were reduced in the absence of SPARC, 
decreases in collagen synthesis did not appear to significantly contribute to reductions in 
bone matrix remodeling.  
SPARC might also influence bone formation through its capacity to bind mineral. In a 
recent study, a peptide (ON29) derived from the mineral-binding region of SPARC 
induced changes to the disordered phase and apatite crystallite morphology in an in vitro 
assay of matrix mineralization [70]. Apatite embedded with ON29 revealed significant 
decreases in the amount of water molecules in the disordered phase of crystal 
mineralization and reductions in phosphate content, however calcium content remain 
unchanged [70]. Decreases in phosphate levels altered the disordered phase of apatite 
crystal growth by inducing needle-like crystal morphology in culture as opposed to plate-
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like morphology. Decreased hydroxyl transfer to the disordered phase was observed with 
peptide treatment, but overall mineral transfer was unaffected [70]. Hence, some aspects 
of the altered phenotype of SPARC-null bones might arise from deficiencies in crystal 
mineralization, specifically in the disordered interface, that in turn might influence 
turnover rates of bone. 
Osteogenesis imperfect (OI) is a heritable bone fragility disorder most frequently 
caused by mutations in genes encoding collagen 1α(I) or collagen 2α(I) subunits [71]. 
Osteoblasts from patients with OI have been reported to display decreased amounts of 
total collagen, SPARC, and proteoglycans as well as defects in metabolism [68, 69]. 
Whether the decreased levels of SPARC are a result of abnormal OI bone matrix or 
whether decreased levels of SPARC contribute to this disease phenotype is not resolved. 
Recently, mutations in the gene encoding SPARC were identified in two individuals with 
recessive OI using whole-exome sequencing [86]. Both of the effected individuals 
demonstrated severe bone fragility and early-onset scoliosis. The mutations in the gene 
encoding SPARC in individuals with OI were found to be glycine to arginine missense 
mutations in exon 7 from one individual and in exon 9 from the second individual [86]. 
The sequence of the collagen-binding site in SPARC is characterized as a “phenylalanine 
(Phe) pocket”.  Arg166 and Glu263 are conserved amino acids in the extracellular Ca2+ 
(EC) binding domain of SPARC. These amino acids form a salt bridge necessary for 
collagen binding in the  “Phe pocket”. Mutations in Arg166 or Glu263 disrupt the pocket 
and significantly reduce SPARC affinity for collagen I. Hence, the collagen-binding 
function of SPARC is hypothesized to play a critical role in collagen deposition in bone. 
Dermal fibroblasts isolated from individuals with SPARC mutations associated with OI 
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exhibited kinetic differences in collagen I triple helical assembly including delayed 
procollagen I secretion [86]. Despite phenotypic similarities, the recent study 
distinguished OI caused by mutations in the gene encoding SPARC from previously 
characterized OI type VI.  SPARC was thus identified as one of the known non-
collagenous proteins in which mutations can cause a severe form of OI. 
SPARC is expressed by osteoblasts undergoing active matrix deposition. 
Interestingly, during in vitro differentiation of osteoblasts in WT cells, SPARC mRNA 
levels remain relatively constant [87]. However, levels of SPARC protein were shown to 
increase during the matrix deposition phase of osteoblast culture differentiation. Levels of 
SPARC protein are highest at times coinciding with initial stages of differentiation and 
subsequently decrease as cells mature and begin to express mature osteoblast markers 
[87]. The differences in expression of SPARC protein versus mRNA suggested a 
significant role for post-transcriptional regulation of SPARC in osteoblasts.  Notably, 
SPARC mRNA has a significantly long half-life, which would be predicted to affect the 
efficacy of transcriptional regulation as a primary mediator of expression. Regions in the 
3’UTR of SPARC mRNA contain highly conserved sequences that interact with miR29.  
Kapinas et al, presented strong evidence that post-transcriptional regulation of SPARC 
mRNA by members of the miR-29 family was a primary mechanism by which levels of 
SPARC were regulated in osteoblasts. Increased levels of miR-29 during osteoblast 
differentiation correlates with decreased amounts of SPARC protein levels [87].  
Delany et al. have reported that osteoblast precursors were reduced in SPARC-null 
mice and that induction of osteoblast differentiation from SPARC-null bone marrow 
derived cells was impaired [88]. Cell populations isolated from SPARC-null bone 
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marrow demonstrated fewer osteoblast cells when grown under conditions favoring 
osteoblastogenesis. Concomitantly, a higher number of adipocytes were detected in 
SPARC-null versus WT cultures in which SPARC-null cells expressed higher levels of 
adipsin mRNA, a marker of mature adipocytes [88]. Interestingly, diminished cell 
survival also indicative of SPARC-null bone marrow derived cells was rescued by 
reintroduction of SPARC expression through transfection of SPARC-expressing vectors 
but not by incubation with recombinant SPARC protein. SPARC-null osteoblasts, 
differentiated in vitro, showed similar levels of osteoblast differentiation markers: 
osteopontin and bone sialoprotein. Significantly lower levels of osteocalcin mRNA were 
detected versus WT cells. In addition, attenuated formation of mineralized nodules was 
observed in SPARC-null cultures that suggested that SPARC-null osteoblast do not 
undergo a complete process of maturation [88]. Hence, cultures derived from SPARC-
null mice displayed a higher propensity for the differentiation of adipocytes at the 
expense of competent osteoblast differentiation. Interestingly, an increase in adiposity of 
SPARC-null bone marrow has also been described [89]. 
Parathyroid hormone (PTH) is a potent stimulator of bone remodeling that supports 
formation of new bone over those processes that influence bone resorption. Presently, 
intermittent administration of PTH is the most commonly used bone-anabolic therapeutic 
option for osteoporosis patients. To test whether SPARC might influence PTH efficacy, 
WT and SPARC-null mice were treated with PTH and assessed for differences in bone 
formation [82]. As expected, PTH treatment elevated whole body bone mineral density in 
WT mice however, notably, no increases in bone mineral density were observed in 
SPARC-null mice. Although the osteoblast response was similar in WT and SPARC-null 
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mice treated with PTH, SPARC-null mice had a significant increase in the number of 
osteoclasts and the associated eroded surface of bone in comparison to WT mice treated 
with PTH [82]. PTH treatment is known to result in the formation of multinucleated 
osteoclasts through the increase in expression of RANK-ligand accompanied by a 
decrease in osteoprotegerin. Interestingly, bone marrow cells isolated from SPARC-null 
mice treated with PTH showed a greater propensity for osteoclast differentiation in 
comparison to WT cultures and suggested that in the absence of SPARC, PTH has an 
enhanced effect on osteoclastogenesis over that of WT cells [82]. Observed increases in 
levels of expression of RANKL in PTH treated SPARC-null mice might contribute to 
increased osteoclast formation although other cellular mechanisms could also be 
important as expression of osteoprotegerin (OPG) was also increased in SPARC-null 
cells rendering the RANKL/OPG ratio relatively unchanged [82].  
Osteoclasts and macrophages arise from the same precursor monocyte cell lineage 
that also derives from bone marrow cell populations.  Expression of SPARC by some 
monocyte/macrophage cell lines and by monocyte/macrophage populations in tissues has 
been reported [90-92].  To date, the expression of SPARC by osteoclasts, either in vitro 
or in vivo, has not been reported. As mentioned above, in PTH-treated mice, SPARC 
appeared to limit osteoclast formation however the mechanism by which SPARC acts to 
influence osteoclast activity is not defined and might involve 1) direct interaction of 
extracellular SPARC with osteoclasts, 2) an influence on other cell types that support 
osteoclast activity such as immune cells or osteoblasts, or 3) reside in differences in 
mineralized ECM assembled in the absence of SPARC.  
	 42	
The mechanisms by which SPARC influences bone formation, maintenance, and 
repair might occur through multiple pathways that include the regulation of procollagen 
processing and assembly in the bone matrix, cross-linking, mineralization, and/or 
osteoblast/osteoclast differentiation and activity. As each of these processes are tightly 
linked to one another, perturbations in one pathway might induce a ripple effect leading 
to consequences for other mediators of bone biology. Given the close association of 
SPARC with collagen I expression in both mineralized and non-mineralized tissues and 
the capacity of SPARC to bind to collagens, strongly suggests that SPARC is critical in 
the production and/or deposition of collagen. The recent identification of mutations in 
SPARC specifically in the collagen binding pocket region that associate with 
osteogenesis imperfecta lend credence to the concept that the collagen-binding function 
of SPARC is essential for proper ECM assembly and architecture.  
 
5. Absence of SPARC exacerbates PD  
SPARC expression plays aberrant roles in regulating progression of inflammatory 
diseases through the ability to attract monocytes and stimulate cell migration mediated by 
integrin and CD44 cell surface binding [93, 94]. Extensive research has demonstrated the 
involvement of SPARC in cell invasion and metastasis in tumor progression, obesity-
linked liver inflammation, cardiac and lung fibrosis-induced inflammation, and diabetes 
mellitus [45, 53, 95-97].  Macrophages, activated T cells, and NK cells express SPARC. 
Expression of SPARC during inflammatory disease states down regulates anti-
inflammatory cytokines IL-10 and IL-12 and causes induction of pro-inflammatory 
cytokines IL-6, TNF-α, and NF-κB [98, 99]. Pro-inflammatory cytokines activated by 
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SPARC enhance macrophage cell migration, survival, and cytokine production [94]. 
Activation of NF-κB, the “master gene promoter of inflammation” activates the PI3K/Akt 
pathway to prevent cell apoptosis during inflammation [100]. SPARC expression by 
macrophages enhances endothelial cell extravasation through interaction with VCAM-1 
cell surface molecule, which induces actin cytoskeletal rearrangement and intracellular 
gaps [101].   
The structural integrity of the periodontal ligament is attributed to the high amount of 
collagen type I content. SPARC is expressed in all tissues of the periodontium; PDL, 
cementum, and alveolar bone [58, 77, 102]. Saliva from patients with PD exhibited 
increased levels of SPARC correlating with decreased alveolar bone loss [103, 104]. 
Various murine models of PD have been utilized to study inflammatory response and 
disease progression (summarized in Table 4). Injection of bacterial LPS into the PDL is 
one model used to mimic the PD state by inducing an inflammatory response [105]. 
Previous reports from our laboratory indicated increased loss of alveolar bone volume 
fraction and PDL degradation following LPS injections in the absence of SPARC 
compared to WT counterparts. Relative bone loss of SPARC-null mandibles following 
LPS injections was 2.2 fold higher compared to the bone loss of WT mandibles. As 
expected, injection of LPS resulted in robust increases of inflammatory cell infiltrate to 
PDL in WT animals. Surprisingly, the percent of inflammatory cells in SPARC-null PDL 
following LPS-injection was not only reduced compared to WT LPS-injections but was 
even reduced compared to PBS control injections. PDL loss of collagen induced by LPS 
was more extensive in the absence of SPARC compared to WT animals. 
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Table 4. Experimental Murine Models of PD  
Model Implementation Method Advantages Disadvantages 
Lipopolysaccharide 
(LPS) 
• Injection [106] 







Live bacteria  • Injection 
• Oral Gavage  






Allows for isolation 
of specific pathogens 
and characterization 










Critical size defects  • Surgical removal of 
periodontal tissues and/or 














of progressive  
tissue(s) 
degeneration 
High sucrose diet • Secondary method used in 















• Trinitrobenzene sulfonic acid 
(TNBS) or dextran sulfate 
sodium (DSS) treated food 
[114] 
Quick, easy 









ex vivo Mandibular 
Slice Culture 
• Embryonic (E12) tooth germ 










Ligature*  • Silk or cotton suture tied 
around molar(s) to create 
periodontal pocket between 
gingival tissue and tooth 
cementum and allow for 
bacterial colonization [116] 
• Sometimes soaked in LPS/live 
bacteria/combined with high 
sucrose diet  
Highly indicative of 
natural disease 
progression if used 








*Model implemented throughout dissertation experiments  
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The number of Sharpey’s fibers weaving into alveolar bone was reduced in SPARC-null 
PDL following LPS challenge and the width of the same fibers was decreased in SPARC-
null PDL with both PBS and LPS injections compared to WT PDL [117]. Increased 
alveolar bone loss in SPARC-null mandible was predicted given the role of SPARC in 
formation of mineralized matrix. Defects in SPARC-null bone phenotype predispose 
mice to accelerated bone loss following LPS challenge. Reductions in SPARC-null PDL 
inflammatory cell populations following LPS injections reflect studies that reported an 
impaired ability of SPARC-null mice to mount an immune response following LPS 
footpad challenge [118]. Loss of PDL collagen content and integrity suggests a critical 
role of SPARC to resist collagenase digestion of fibers during an inflammatory disease 
state. The reduced number of Sharpey’s fibers following LPS challenge in SPARC-null 
PDL is attributed to compensatory mechanisms of an inherently weaker ECM and 
alveolar bone composition compared to WT counterparts [117]. PD progression resulting 
in an exasperated phenotype in the absence of SPARC is depicted in Figure 5.   
 
6. TG-mediated collagen crosslinking in PDL  
Transglutaminases (TGs) are a family of 8 proteins expressed throughout the 
body that catalyze extracellular crosslinking [119]. TGs catalyze an irreversible covalent 
acyl exchange between a glutamine and a lysine resulting in an isopeptide bond (Fig. 6). 
Tissue transglutaminase, TG2, is the most ubiquitously expressed TG family member 
[119]. Unlike the 7 other TG family members, TG2 is uniquely capable of acting as a 
GTP-ase and a protein disulfide isomerase.  
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Figure 5. The absence of SPARC increases PDL collagen degradation and alveolar 
bone resorption during PD. 1) The absence of SPARC decreases monocyte 
extravasation/macrophage infiltration to site of inflammation 2) Aberrant procollagen 
processing and reduced collagen deposition in SPARC-null animals results in a PDL 
prone to degradation 3) Decreased mineral density of SPARC-null bones predisposes 






Exactly how TG2 is secreted into the extracellular space is unknown since the mRNA 
encoding TG2 does not possess a secretion signal.  Multiple labs have identified TG2 
localization to the ECM in vivo and in vitro, TG2 cross-links in the ECM, and TG2 
protein in cell culture media [120, 121].  
Human TG2 has four domains: an N-terminal domain capable of binding 
fibronectin and a catalytic domain triad composed of cysteine-histidine-aspartic acid 
residues and 2 beta-barrels. The catalytic triad of TG2 enables it to bind and use guanine 
nucleotides to regulate transamidation unique from other TG family members. TG2 has 
been shown to cross-link ECM proteins such as fibronectin and fibrillar collagens. 
Studies carried out in cartilage revealed that SPARC could also serve as a substrate for 
TG [80]. The catalytic function of TG2 and Factor XIII (plasma TG) is defined as a 
protein transamidation reaction that occurs between glutamine and lysine residues 
resulting in the formation of a γ-glutamyl-ε−lysyl covalent bond. The crosslinking of 
ECM proteins by TG is predicted to promote assembly and/or enhance stabilization of 
collagenous and noncollagenous ECMs [119].  
TG2 is capable of cross-linking the ECM protein fibronectin during fibril 
assembly by acting as a co-receptor for the 42kDa fragment of fibronectin [122]. The 
binding of TG2 to fibronectin facilitates association with β1 and β3-integrins. The 
association of fibronectin with β-integrins mediated by TG2 promotes cell adhesion and 
migration [121]. TG2 also enhances cell spreading and adhesion in fibroblasts in vitro 
[121]. TG2 has a TGF-β1 response element located in the promoter region. An increase 
in TG2 in fibroblasts resulted in TGF-β1 induction that was NF-κB dependent and a 


















Mice lacking TG2 display several abnormalities in their ECM structure and 
function. TG2-null mice develop cataracts at an early age compared to WT counterparts 
and display gluten sensitivity due to increased cross-linking of glial peptides. These mice 
have reports of neurodegeneration, increased melanoma tumor size, and aberrant tissue 
remodeling in heart, liver, kidney, and bone [124-126]. TG2-null mice do not develop 
interstitial fibrosis and have no alterations in collagen synthesis or deposition compared 
to WT mice [125]. Endothelial cells, smooth muscle cells, and fibroblasts constitutively 
express TG2 [124]. Multiple studies have implicated TG2 in ECM homeostasis via 
transamidation of fibronectin and collagen. Aberrant TG2 activity is associated with 
states of fibrosis, wound healing, and altered collagen I cross-linking.    
The expression of SPARC was recently shown to influence TG activity in PDL. 
As mentioned previously, an absence of SPARC expression results in decreased levels of 
collagen I in many connective tissues. In addition to reduced collagen content, collagen 
fibrils assembled in the absence of SPARC are smaller and more uniform in diameter 
versus those in WT tissues, including PDL. Accordingly, SPARC-null PDL was shown to 
have decreased mechanical strength in comparison to WT [66]. SPARC-null PDL also 
demonstrated increased TG activity. Specifically, TG activity on collagen I was enhanced 
with abrogated SPARC expression. Administration of TG inhibitors to SPARC-null PDL 
resulted in increased collagen content and the generation of larger collagen fibers. The 
increase in collagen content and the rescued morphology of the collagen fibers was 
associated with enhanced mechanical strength of the PDL [66]. SPARC bound to 
collagen is predicted to reduce accessibility of TGs to certain glutamine and/or lysine 
residues on collagen. Hence, over-modification by TG on collagen might lock collagen 
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fibrils into a smaller diameter preventing further fiber expansion and reducing overall 
collagen content and mechanical strength of soft tissues. 
 
7. TG in inflammatory PD  
Penetration and damage of the gingival epithelial layer by pathogenic bacteria are 
important steps in PD pathogenesis. Alterations between the gingival epithelia and 
attachment to the underlying ECM and connective tissues disrupt junctional epithelium 
homeostasis and migration during progressive PD. Curro et al. reported increased TG2 
mRNA levels along with reductions in TG1 and TG3 mRNA and protein levels in 
patients with chronic PD compared to healthy controls [127]. Clinical studies assessing 
gingival overgrowth in patients with PD reported significant increases in TG2 expression 
histologically in gingival biopsies compared to healthy patients, implicating the role of 
TG2 in gingival matrix remodeling [128, 129].  
Cui et al. demonstrated in osteoblast cultures that Factor XIII, a circulating TG, 
catalyzed the cross-linking of fibronectin from serum (plasma fibronectin; pFn), as 
opposed to the EDA-splice variant of fibronectin endogenously expressed by osteoblasts 
(cellular Fn; cFn) [119]. Formation of a cross-linked fibronectin matrix derived from pFn 
was required for subsequent deposition and assembly of a collagen network. Inhibition of 
Factor XIII activity, but not that of TG2, decreased collagen deposition and 
mineralization in osteoblast cultures [119]. Hence, cross-linking of pFn by Factor XIII 
was predicted to be an essential phase of bone formation that precedes collagen 
deposition. Another study revealed enhanced osteoblast cell adhesion properties of two 
matricellular proteins mediated by TG2 crosslinks: osteopontin (OPN) and bone 
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sialoprotein (BSP). It was confirmed that both OPN and BSP serve as substrates for TG2 
and that their modification by TG2 enhanced the formation of cellular extensions in 
osteoblast cell cultures. Similar to Factor XIII, TG2 is found to localize to osteoid, 
osteoblasts, and osteocytes and it is hypothesized that these two enzymes work 
synergistically to oligomerize substrates [130]. TG might also be an essential factor in 
crosslinking of collagen fibers in bone formation. TG2 activity specifically in alveolar 
bone during PD has not been reported. Given the implications for TG2 activity during 
homeostatic bone growth and development it is likely that TG2 activity axis is altered in 
alveolar bone during inflammatory PD.   
During PD, macrophages and T lymphocytes produce inflammatory mediators; IL-1, 
IL-6, TNF-α, and prostaglandin E2, which induce bone resorption indirectly by 
stimulating osteoblasts to produce receptor activator of nuclear factor kappa-B ligand 
(RANKL) [131]. RANKL is the ligand receptor for RANK found on the surface 
osteoblasts and plays a critical role in bone metabolism by activating osteoclasts and their 
subsequent bone resorption. Osteoprotegerin (OPG) is a decoy receptor for RANKL 
produced by osteoblasts and fibroblasts. The binding of OPG to RANKL prevents NF-κB 
activation and osteoclast differentiation from monocyte precursors [132]. Increased levels 
of RANKL mRNA are associated with chronic PD and corresponding increases in 
alveolar bone resorption [131]. Cytokines and growth factors secreted during 
inflammatory states regulate TG2 expression levels [133]. Concomitant TG2 mRNA up-
regulation with increased cytokine mRNA levels were reported in cultured human PDL 
(HPDL) from PD patients compared to healthy HPDL cells. Human THP-1 cells 
differentiated to macrophages exhibited reductions of TG2 activity associated with loss 
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of NF-κB activation and reduced RANKL expression. The authors suggest a role of 
TG2/NF-κB axis during the inflammatory response by increasing RANKL/OPG mRNA 
expression in patients with PD. Inhibition of TG activity in differentiated THP-1 cell 
cultures reduced NF-κB and RANKL mRNA levels. Increased TG2 expression in HPDL 
cells from patients with PD suggests a role for TG2 in promoting molecular mechanisms 
that might contribute to bone resorption in these patients [134]. Currently, there is no 
published literature investigating TG activity in PDL as it relates to collagen 
assembly/remodeling during PD. One aim of this dissertation work is to explore the 
biological role of TG2 specifically in PDL collagen biology during inflammatory PD 









Figure 7. Proposed Hypothesis. Increased activation of TG and TG-mediated collagen 
cross-links in PD results in PDL degradation and smaller collagen fibers, which is further 





Figure 8. Cellular Schematic of Proposed Hypothesis. Collagen secreted from WT 
PDL fibroblast assembles with the help of chaperone protein SPARC into thick fibrils. 
Increased TG expression during inflammatory PD results in partial collagen fiber cross-
linking into tighter thinner fibers, while collagen fibers bound by SPARC assemble into 
homeostatic thicker fibers resulting in an intermediate fibril formation. In the absence of 
SPARC, TG is able to bind increased levels of secreted collagen and cross-link fibers into 
tight, thin fibers. The thin fibers formed by TG cross-linking are mechanically weaker, 





























Animal Use and Care 
SPARC-null mice with global abrogation of SPARC expression and mice carrying the 
exon-2 deleted procollagen α1(I) gene were crossed to generate SPARC-null/exon-2 
deleted (double-null) mice as previously described [135]. Strategy to generate SPARC-
null mice is described in [50] and exon-2 deleted mice in [136]. Single heterozygotes 
(KO/het and het/KO) were bred to obtain wild-type controls (wt/wt). Genotyping of all 
mice was performed by tail clip DNA extraction followed by qPCR conducted with 
specific forward and reverse primers utilizing the GoTaq PCR Core System I (Promega; 
Madison, WI). All transgenic lines were maintained on a C57Bl/6/129SV mixed 
background. Animals were euthanized via CO2 asphyxiation, followed by cervical 
dislocation. Mice were housed in the Ralph H. Johnson Veteran’s Administration (VA) 
animal facility and were supplied with a standard diet of hard chow. The described 
experiments in this study were conducted under an animal protocol approved by the 
Institutional Animal Care and Use Committee (IACUC) of the Medical University of 
South Carolina and the Veterans Affairs Medical Center, Charleston, South Carolina, 
USA. 
Histological Analysis of Collagen Morphology and Collagen Volume Fraction 
Mandibles and maxillae from mice were dissected, fixed over night in zinc-formalin, and 
decalcified in 0.5M EDTA changed daily for 2 weeks at room temperature. Following 
decalcification, jaws were dehydrated in graded ethanol changes, embedded in paraffin, 
and sectioned (5-7µm). Sections were mounted on glass slides, rehydrated in xylene 
followed by incubation in a series of graded ethanol washes, washed in phosphate 
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buffered saline containing 2% tween (PBST) for 10 minutes, then blocked in 3% donkey 
serum in PBST.  
Picro Sirius Red Staining 
Picro Sirius Red (PSR) staining was performed as follows. Slides were stained in iron 
hematoxylin for 10 minutes followed by a running water rinse (10 min). The slides were 
then stained in PSR (Sigma-Aldrich; St Louis, MO) for 1 hour followed by three 5-min 
rinses in 1% acetic acid, dehydrated, and mounted with Clarion mounting medium and 
cover slips. Slides were imaged using a 40X objective on an Olympus Bx50WI 
microscope (Center Valley, PA) equipped with Infinity 2 Capture software (Electron 
Microscope Services; Hatfield, PA). Slides were visualized with polarized light under 
which thick collagen fibers appear bright red or red/orange and thin collagen fibers 
appear green/yellow in color easily differentiated against a black background. Slides were 
also visualized and imaged under bright light, under which all collagen appears red 
against a yellow background. Quantitative morphometric analysis of images was 
conducted using Visiopharm Integrator System (VIS, version 3.2.9.0) with parameters set 
to measure total area of PDL, background area, total collagen area, thick collagen fiber 
area (red/orange), and thin collagen fiber area (green/yellow). Bright field PSR images 
were quantified for percent total collagen using VIS with parameters set to measure total 







Herovici histological staining was performed utilizing a kit (American MasterTech, 
KTHER) and following manufacturing procedure guidelines. Slides were stained with 
Weigert’s hematoxylin for 5 min followed by a running water rinse for 45 seconds. 
Herovici’s working solution was applied to slides for 2 minutes followed by a 2 minute 
immersion in 1% acetic acid, dehydrated for 1 min in absolute alcohol (3 changes), 
cleared for 1 min in histoclear (3 changes), and mounted with cytoseal wet mounting 
media. Slides were visualized with bright light using a 40X objective on the same scope 
utilized for PSR above. Newly formed collagen fibers or thin fibers were stained blue, 
homeostatic mature collagen or thick fibers stained red/pink, and nuclei stained black.  
Second-Harmonic Generation  
 
Fresh, un-stained, non-fixed, non-decalcified maxillae were dissected from mice, rinsed 
in PBS, and soaked in 50% glycerol for 1 hour. Jaw specimens were sliced to obtain a flat 
exposed longitudinal slice of PDL tissue using a sledge microtome (SM2400, Leica 
Microsystems GmbH, Wetzlar, Germany) with a freezing stage (Model BFS-30, 
Physitemp, Clifton, NJ) and optimal cutting temperature (OCT) compound (Sakura 
Fineteck 4583, Torrance, CA). Freshly cut specimens were rinsed in PBS to remove 
remaining OCT compound and stored in fresh PBS prior to imaging. Imaging was 
performed using an Olympus Fluoview 1200 MPA (Olympus, Center Valley, PA) with a 
30X oil immersion objective lens (UPLSAPO, 30XSIR; Olympus, Center Valley, PA). 
The excitation laser for SHG was at a wavelength of 860 nm, and the signal was collected 
in the 420-460 nm range. Image resolution was 1024 x 1024 with a field of view of 423 x 
423 µm. For z stack images, slices were taken at a range of 0.2 – 0.5 µm/slice for depths 
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up to 100 µm and attenuation compensation was applied to adjust laser power according 
to laser depth. Images were analyzed using Fiji for Image J to produce a two-dimensional 
discrete frequency Fourier transformation (FFT) along an orthogonal axis to indicate 
image frequency function between 0 and 1. DFT accounts for spatial geometric 
characteristics of an image. The frequency distribution of the transformed image was 
quantified as aspect ratio (AR) using the horizontal and vertical axes of each 2D FFT in 
Matlab software. The frequency distribution of the transformed image was analyzed 
using Matlab software. Entropy of each image was calculated using Matlab to measure 
redundancy of information. Regular repeated patterns result in high entropy values 
indicating high level of organization. Low entropy values indicate increased 
disorganization of image. The inverse of entropy (1/E) was calculated for each image and 
used as the disorganized parameter (DP). Entropy does not take into account spatial 
properties, which is why this calculation was combined with FFT for all SHG images. 
Three-dimension volume and orthogonal reconstructions of z stack images were creating 
using Imaris software.   
Mechanical Testing of Mandibular PDL 
 
Dissected mandibles of mice were secured to a base and a 30G wire threaded underneath 
the crown of the first molar was secured to an upper clamp elevating with a set rate until 
the point of tooth extraction. The force required for extraction was recorded with a load 
cell. Detailed set-up schematic and methods of mechanical testing of murine PDL has 






Mechanical Testing of Maxillary PDL 
 
Following ligature-treatment and TG inhibition in vivo, mandible was dissected and 
discarded from calvaria. Ligature was removed from 2nd maxillary molar and discarded. 
A 40-gauge wire was threaded through the root furcation of the 1st molar on both left and 
right sides in the same manner as previously described for mandibular mechanical 
testing. Smaller gauge wire was required for maxillary molars versus mandibular molars 
to avoid alveolar ridge and/or tooth crown fracture. Additionally, the 1st maxillary molar 
was used for testing due to increased fragility of 2nd maxillary molars. Remainder of 
murine calvaria, with soft tissue and musculature attached, was rinsed in 70% ethanol and 
PBS. Following placement of wires, heads were embedded in plastic resin blocks with 
soft palate and molars exposed (Environmental Technology Inc. Fields Landing, CA). 
Buccal skin flaps were elevated surrounding soft palate to avoid resin infiltration. Square 
resin molds were allowed to polymerize overnight at room temperature. Once fully 
polymerized resin blocks were stored at 4°C until next step. Resin blocks were removed 
from molds and cut down to fit apparatus clamp size using a dremmel. Resin embedding 
and exposure of native tissue at room temperature overnight dehydrated tissues and 
increased stiffness. Cut blocks were rehydrated for 6-8 hours in PBS at room 
temperature. Wires resistant to oxidation must be used to maintain integrity through this 
step. Individual blocks were removed from PBS immediately prior to testing, rinsed in 
dH2O, blotted dry, and mounted on testing apparatus. The smaller, 40-gauge, wires 
utilized in maxillary testing could only withstand a max force of 5.5 newtons before 
failure. Therefore, data is reported as max force instead of mechanical strength for 
maxillary testing.        
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Other Histology and Immunofluorescence of PDL  
 
Hematoxylin & Eosin   
 
Histologically prepared mandibular and maxillary sections were stained with 
hematoxylin and eosin (H&E) and visualized under bright light. Rests of Malassez were 
identified as multi-cellular clusters of epithelial cells within the PDL situated along the 
tooth cementum border. Results of H&E staining were confirmed by 
immunofluorescence using a monoclonal antibody generated against mouse cytokeratin 
(Sigma-Aldrich, St. Louis MO, Fig. 6E-H). A 1:200 primary antibody concentration with 
overnight incubation at 4°C was followed by a 1-hour incubation with a fluorescein 
conjugated anti-mouse secondary antibody at a 1:200 concentration (AlexaFluor 488). 
Secondary-only sections were used as negative controls. Prolong anti-fade containing 
DAPI (Molecular Probes, Eugene, OR) was used to mount cover slips and sections were 
viewed on an Olympus fluorescent microscope.   
Immunofluorescence   
Immunohistochemical staining was performed according to the following protocol. 
Following deparafinization and dehydration, slides were incubated in 1% hydrogen 
peroxide in methanol for 30 min to quench endogenous peroxidase activity. Nonspecific 
binding was blocked by incubating slides in 2% donkey serum in PBS for 30 min at room 
temperature. Slides were incubating in anti-Ki67 (abcam 15580) in a 1:500 concentration 
at 4°C overnight. The slides were sequentially detected with avidin-biotin-peroxidase 
(Thermo Scientific 32020), using 3,3’-diaminobenzidine, tetrahydrochloride (DAB, 
Thermo Scientific 34065) as a substrate. Nuclei were counterstained with 15% Ehrlich’s 
hematoxylin. Normal donkey serum was used in place of the primary antibody as a 
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negative control. Images were quantified for the number of individual rests, for % area 
occupied by the rests within the PDL, and for the number of proliferating (Ki67+) cells.   
Immunohistochemistry  
Immunohistochemical multiple antigen labeling to confirm fibroblast cell type was 
performed by the following protocol. Slides were incubated in anti-Ki67 (abcam 15580) 
in a 1:500 concentration at 4°C overnight and sequentially detected with avidin-biotin-
peroxidase (ABC) and DAB substrate. Following PBST wash and rodent block, slides 
were incubated for 2 hours in mouse monoclonal anti-vimentin (abcam 8978, RV202) in 
a 1:50 concentration at room temperature. Slides were incubated with mouse on mouse 
HRP polymer (Thermo Scientific TL015QHDM) for 1 hour at room temperature, 
washed, developed with ImmPACT VIP substrate (Vector Laboratories SK-4605) for 10 
minutes, dehydrated, cleared, and mounted using cytoseal wet mounting media. No 
counterstain was applied.  
Micro-computed Tomography and Bone Volume Fraction Analysis 
Mandibles and maxillae were harvested from mice at experimental age points. Excess 
soft tissue and surrounding musculature was removed. Non-demineralized jaws were 
washed in PBS and fixed overnight in zinc-formalin at room temperature. Following 
fixation, jaws were rinsed 3 times in dH2O and transferred to 70% EtOH until scanned. 
Specimens were scanning by a Scanco Medical µCT 40 system (Scanco USA, Wayne, 
PA, USA) and analyzed with GE microview software (version viz. +2.0 build 0029) for 
quantification of bone volume fraction (BV/TV). Each scan was reconstructed at a mesh 
size of 18 x 18 x 18 µm to create a 3D digitized image for each specimen. The images 
were then rotated into a standard orientation and a threshold at 1621 was used to 
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distinguish between mineralized and non-mineralized tissue. The region of interest (ROI) 
for the bone volume/tissue volume analysis was based on 3 easily identifiable anatomical 
landmarks of each jaw: 1. Mesial CEJ of 1st molar to distal CEJ of 3rd molar with jaw 
oriented in mid-sagittal view, 2. Tips of crown cusps, and 3. Apical portion of anterior 3rd 
molar root (Fig. 9). Buccal:palatal aspects of ROI box are resized according to landmarks 
and 0.9mm are added to the ROI on the Z-axis. BV/TV was then calculated using the GE 
MicroView software bone analysis module. All µCT scans were blindly assessed and 
quantified by an independent laboratory technician.  
Ligature Model of PD  
Mice at a minimum of 6 weeks of age were individually anesthetized in a 5.0% 
isofluorine chamber supplied 0.6 L/min O2 at 14.7 PSI. Anesthetized mice were 
transferred to a heated operating platform set to 37°C and 630 mA (KE OP-T, Vestavia 
Scientific, Birmingham, AL) and ventilated by nose comb supplied with 2.5% isofluorine 
and 0.6 L/min O2 at 14.7 PSI (Mouse MiniVent, type 845, model D-79323, Hugosachs 
Electronik, Germany). Mandible, maxilla, and cheeks were retracted and a 0.5 metric silk 
ligature (Covidien, VS-809, D3C0135X, Mansfield, MA, USA) was placed around the 
left maxillary second molar, following a previously described protocol [116], using a 
Zeiss dissecting microscope (OPMI 1-H, 93534) (Fig. 10). Right maxillary molars were 
left untreated to serve as internal controls. Ligatures were left in place for 5- and 14-day 
time points and checked to ensure secure placement every other day. On day of sacrifice, 
animals were euthanized by CO2 asphyxiation followed by cervical dislocation. Silk 
ligatures were removed from maxillae and discarded prior to further experimentation 
(except in the case of organ culture).  
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Figure 9. ROI Anatomical Landmarks Used for Micro-Computed Tomography 






























F4/80+ Macrophage Immunohistochemistry   
Slides were prepared from sectioned ligature-treated and control jaws as described above 
and incubated in anti-F4/80 (LifeTechnologies MF48000, Frederick, MD, USA) in a 
1:200 concentration overnight at 4°C followed by PBST washes and incubation in 
secondary antibody at 1:200 concentration for 1 hour at room temperature. 
Immunoreactivity was detected with ABC and DAB substrate. Secondary-only sections 
were used as controls.    
Peripheral Blood Lineage Tracing  
Mononuclear Cell Preparation 
To assess potential inherent differences in hematopoietic cell lineages in WT versus 
SPARC-null mice a peripheral blood lineage panel was performed. Peripheral blood 
mononuclear cells were prepared using fresh whole blood (80-100µl) collected from 
mouse (age 3-4 months, n=3 males and 3 females/genotype) by tail clip. Heparin was 
added to each sample to prevent blood coagulation. Each sample was divided into 3 wells 
and stained with 3 primary antibodies: GR1/Mac1, CD4/CD8, and NK/B220 at a 10ug/ml 
concentration. One sample was divided into 6 wells and additionally stained with 
allophycocyanin (APC) and phycoerythrin (PE) for isotype controls and one left 
unstained for a “cells-only” control. All antibodies were purchased from BD Biosciences. 
Cells were incubated on ice for 20 minutes. Pharmlyse was added to each sample and 
incubated on ice for additional 15 minutes. Following lysing, samples were washed in 
0.1% BSA/PBS, spun down at 200xg for 5 minutes, decanted, and resuspended in PBS in 
preparation for FACS analysis.     
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Flow Cytometric Analysis  
Freshly prepared PB samples were analyzed by a FACSCalibur flow cytometer (Becton 
Dickinson, San Jose, CA, USA). Live/dead gating was not compensated for with 
propedium iodine (PI) since fresh PB protocol is quick, lacks manipulations, and thus is 
expected to have very low to no dead cells. Gates were set using isotype controls and data 
was collected for the first 10,000 events.    
TRAP Staining  
For enumeration of multi-nucleated osteoclasts, tartrate-resistant acid phosphatase 
(TRAP) staining was performed on 5-day and 14-day ligature and control sections from 
WT and SPARC-null mice by means of a Leukocyte Acid Phosphatase kit (Sigma, St. 
Louis, MO, USA). Active osteoclasts were defined as multinucleated (≥3) TRAP-positive 
cells in contact with the bone surface. Images were captured on the Olympus Bx50WI 
microscope at 4x, 20x, and 40x objectives. Enumeration of osteoclasts was performed 
using the VIS software.  
Alkaline Phosphatase (ALP) Staining  
To characterize and quantify osteoblast cell population response to ligature-induced 
inflammation, ALP activity was detected histologically. Following deparaffinization, 
sectioned slides from WT and SPARC-null control and ligature specimens were 
incubated for 1 min in microwaved sodium citrate buffer (pH 6.0) and allowed to cool to 
room temperature in ddH2O. Endogenous peroxidases were blocked in a 3% hydrogen 
peroxide + methanol solution for 10 minutes. Sections were washed 3x in PBS followed 
by a 10 min block in goat serum. Slides were incubated in primary anti-alkaline 
phosphatase rabbit monoclonal antibody (ab108337) in a 1:250 concentration for 1 hour 
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at room temperature. Following PBS washes, slides were incubated in secondary 
antibody (ab6721) in a 1:250 concentration for 1 hour, washed, detected with DAB 
substrate, and counterstained with Harris hematoxylin (diluted 1:10 in ddH2O) for 30 
seconds then coverslips were mounted with Permount mounting medium. Images were 
captured on the Olympus microscope at 20x and 40x objectives and ALP reactivity was 
quantified utilizing VIS software.  
TG Expression and Epitope Staining  
To assess differences in TG2 expression levels and cross-linking activity through the 
formation of N-ε-γ-glutamyl lysine bonds immunohistochemistry was performed on WT 
and SPARC-null maxillary sections following 5-day ligature treatment and corresponding 
controls. Sections were prepared and processed through the IHC DAB protocol described 
above. WT and SPARC-null slides with and without 5-day ligature treatment were 
incubated in polyclonal anti-TG2 primary antibody (covalab, pab0024-P, Villeurbanne, 
France) for TG2 expression and in a monoclonal anti-N-(L-glutamyl)-L-lysine isopeptide 
primary antibody (covalab, mab0009-P, Villeurbanne, France) for TG2 cross-linking 
activity at a concentration of 1:200 at 4°C overnight and corresponding secondary 
antibodies (anti-rabbit and anti-mouse, respectively) at a concentration of 1:200 for 1 
hour at room temperature. Secondary only sections were used as controls. Slides were 
mounted with glass coverlips using Permount.  
TG Inhibition  
In vivo Inhibition of TG with Biotinylated Cadaverine Injections 
Twenty-two 2-3-month old WT C57Bl/6J male mice were used. Ten mice were used for 
protein analysis of biotinylated cadaverine PDL incorporation. Each mouse was 
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anesthetized and the left 2nd maxillary molar was ligated as described above. Following 
ligation, each mouse was injected with either 2 µL of biotinylated cadaverine (BC) 
(Sigma-Aldirch, A5348) (2 mM in DMSO) (n = 5) or 2 µL of DMSO vehicle (Invitrogen 
(n = 5) in the PDL around the 2nd maxillary molar on both the left (ligated) and the right 
(non-ligated control) side. Mice received injections daily for 4 days. A second set of mice 
(n = 6: BC n = 3, DMSO n = 3)) were ligated and injected for second harmonic 
generation imaging. A third set of mice (n = 6: BC n = 3, DMSO n = 3) were ligated and 
injected for immunohistochemistry. At day four, 3 hours following same-day injection, 
the mice were harvested and jaws were collected for organ culture described below.  
In vitro Organ Culture  
Maxillae were removed from 2-3 month old WT mice and dissected free of muscle and 
loose tissue. Jaws from a single mouse were placed in one well of a 24-well plate with 1 
mL of growth media (DMEM 10% FCS, 0.2% primocin, 50µg/mL ascorabate). Growth 
media was supplemented with BC (2 µM) or equal volumes of vehicle control (DMSO) 
as warranted by experimental design. Jaws were then incubated at 37°C, with 5% CO2 for 
24 hours prior to molar extraction. Molars from a single mouse (3 left molars, 3 right 
molars) were separated and placed in 100 µL of 2.5% SDS in dH2O, supplemented with 
protease inhibitors (Roche, Indiannapolis, IN, USA) or were freshly harvested for SHG 
imaging or decalcified as described previously and processed for immunohistochemistry. 
Extracted molars receiving same treatment were pooled into one sample. Four treatment 
groups from n = 10 WT mice were as follows: n = 30 left molars DMSO + ligature, 30 
right molars DMSO no ligature control, 30 left molars BC + ligature, 30 right molars BC 
no ligature control. Teeth were stored at -80°C overnight and then tumbled at 4°C for 4 
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hours to extract PDL protein. Teeth extracted in SDS buffer were boiled, vortexed, and 
then boiled for an additional 5 min. After boiling, these samples were centrifuge at 
10,000g for 10 min, and the supernatants used for immunoblot analysis (Fig. 11).    
Immunoblotting  
Equal amounts of protein were separated by SDS-PAGE analysis followed by staining 
with Coomassie brilliant blue to confirm equal loading or transferred to nitrocellulose 
membranes. Membranes were blocked in 3% bovine serum albumin in Tris-buffered 
saline with 0.2% Tween (TBST) for 1 hour at room temperature. Membranes were then 
incubated with primary antibodies, anti-collagen α1(I) (1:10,000 dilution; MD 
Biosciences, St. Paul, MN, USA), avidin-horseradish peroxidase (HRP) (to detect BC) 
(Vector Laboratories, Burlingame, CA, USA), anti-TG2 (1:10,000 dilution; Covalab, 
pab0024-P, Villeurbanne, France), and anti-SPARC (1:5,000 dilution, R&D Systems, 
942-SP, Minneapolis, MN, USA) followed by appropriate secondary antibodies (Vector 
Laboratories) and detection with chemiluminescence reagent (Pierce, Grand Island, NY, 
USA). The intensity of bands generated from TG modification by labeled donor substrate 
was quantified with NIH Image J software.  
Human PDL Fibroblast Cell Culture  
Extracted teeth were collected (in DMEM/20%FBS/2%PS/250µg/ml gentamicin 
sulfate/2.5 µg/ml amphotericin B) from MUSC Department of Oral and Maxillofacial 
Surgery in collaboration with Dr. Meenal Mehrotra in the Department of Pathology and 
Laboratory Medicine. Routine wisdom teeth extractions were used as healthy controls.  
	 71	
 











Teeth extracted from patients suffering from chronic inflammatory PD were designated 
to the diseased group. Teeth were transported on ice and rinsed thoroughly in PBS. Tooth 
roots were scraped with a scalpel to collect PDL tissue, which was pooled into 1 tube and 
washed 2-3 times with PBS. Tissue was digested in 750 µL solution of dispase (4mg/ml) 
and collagenase (3mg/ml) in PBS for 1-2 hours at 37°C, vortexing in between. Following 
digestion, 2 mL of media was added to the tube and vortexed. The solution was filtered 
through 70uM filter and collected in a new tube. PDL tissue was washed once with 
media, filtered, and added to the new tube. Mixture was centrifuged and the cell pellet 
washed once with media. Cells were then plated in culture medium containing ascorbic 
acid (AA) and L-glutamine (L-glut) for 2-3 weeks. Cells and media were collected at 
passage 5 for immunoblotting with antibodies listed above.  
Statistical Analysis  
The number of experimental animals used was based on previous results. A paired 
student’s t-test was used to calculate p-values within genotypes. For comparisons 
between genotypes with one condition a student’s t-test was used to calculate p-values. 
For comparisons between genotypes with more than one condition, ANOVA analysis 
followed by Tukey test was used to calculate p-values. For all analyses, p < 0.05 was 
































Section 1. SPARC and the N-propeptide of collagen I influence fibroblast 
proliferation and collagen assembly in the PDL.  
The function of the N-propeptide of Collagen I is undefined. Results from 
Bornstein et al. and Card et al. suggested no phenotype in transgenic mice with an N-
propeptide deletion and only observed a phenotype in dermal tissues when the N-
propeptide deletion was combined with an absence of SPARC [135, 136]. Herein, we aim 
to examine the N-propeptide phenotype, and potential functional role, in the PDL. 
Decreases in Collagen Content and Fiber Size of SPARC-null/exon-2 deleted PDL 
 Previously, decreases in collagen content and fiber thickness were reported in 
SPARC-null (ko/wt) PDL compared to WT [58]. PSR-stained images were used to 
evaluate collagen content and fiber thickness in PDL of ko/ko, ko/wt, and exon-2 deleted 
mice (wt/ko) in comparison to wt/wt. Representative images from 1-month old mice are 
shown in Figure 12, A-D. Quantification of PSR images viewed under polarized light 
demonstrated reduced amounts of total collagen in SPARC-null (ko/wt), exon 2-deleted 
(wt/ko) and double-null (ko/ko) mice at 1- and 3-months of age versus WT (wt/wt) (Fig. 
11E). The most dramatic decrease in total collagen in double-null mice was detected at 3 
months at which time the double-null PDL had significantly less collagen than either 
single transgenic. Whereas exon-2 deleted (wt/ko) mice exhibited reductions in total 
collagen at 1 and 3 months, at 12 months of age, the PDL of these mice exhibited 
increased amounts of total collagen versus WT mice and indicated an age-dependent 
effect in the N-propeptide deleted mice (Fig. 12E).  
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Figure 12. Total collagen I content is reduced in double-null PDL. Representative 
Picro Sirius Red (PSR) stained images of 1-month PDL from wt/wt (A), wt/ko (B), ko/wt 
(C), and ko/ko (D) viewed under polarized light. Images taken at 40X magnification. n=5 
mice/genotype, 5 sections/mouse. Bar in A=25 µm and applies to all panels. E. Total 
collagen I content of PDL at 1-, 3-, and 12-month age points. *p<0.05 compared to 
wt/wt. #p<0.05 compared to ko/ko.   
 Figure 13. Percent total collagen I content 
is reduced in double-null PDL at all age 
points. Representative bright field images of 
Picro Sirius Red stained 1-month PDL from 
wt/wt (A), wt/ko (B), ko/wt (C), ko/ko (D). 
Images taken at 40X magnification. Images 
are oriented with alveolar bone on bottom, 
PDL center, and tooth cementum on top. n=5 
mice, 5 sections/mouse. Bar in A=25 µm and 
applies to all panels. Method of 
quantification is shown in E followed by 
graphical representation in F of PDL at 1-, 3-
, and 12-month age points. *p<0.05 vs. 
wt/wt. #<0.05 vs. ko/ko.   
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Likewise, double-null mice at 12 months of age demonstrated collagen content similar to 
that of SPARC-null mice suggesting the activity of the N-propeptide to influence 
collagen content was decreased at 12 months of age. Results reflecting percent total PDL 
collagen content were also assessed using bright field PSR images and quantification 
(Fig. 13).  
Morphological analysis of PSR-stained images revealed thinner collagen fibers in 
each of the transgenic mice at 1- and 3-months of age versus that in WT PDL (Fig. 14). 
At 3 months of age, double-null PDL had significantly less thick collagen fiber content 
than either of the single transgenics. At 12 months of age, mice lacking exon 2 
demonstrated significantly more thick fiber content in the PDL than WT, SPARC-null, or 
double null PDL. The persistence of thin fiber content in SPARC-null PDL was also 
reflected in the thin fiber content of double null mice at 12 months of age (Fig. 14). 
Hence, similar to collagen content, effects of the N-propeptide in regulating collagen 
fiber assembly appear to shift with age whereas the lack of SPARC in double-null mice 
appears to dominate collagen fiber morphology at 12 months.  
Herovici stained 1- and 12-month PDL sections reveal distinct staining patterns of 
collagen fibers in each genotype (Fig. 15). Thicker collagen fibers stain red/pink with 
Herovici stain whereas thinner fibers appear blue. At 1 month of age, wt/wt PDL stained 
with Herovici’s stain showed the presence of both red and blue fibers (Fig. 15A) whereas 
in wt/wt PDL at 12 months of age, red fibers appeared to dominate the sections (Fig. 
15E), suggesting maturation of collagen fibers with age. Interestingly, an apparent 




Figure 14. A consistent reduction in collagen I fiber size observed in double-null 
PDL from 1-month to 12-months of age. Collagen fiber morphology represented by 
thin vs. thick fibers quantified from PSR histology for three age points. n=5 
mice/genotype, 5 sections/mouse. *p<0.05 compared to wt/wt counterparts, #p<0.05 










Figure 15. Collagen fiber morphology altered in double-null PDL at 1- and 12-
month age points. Representative images of Herovici stained PDL from wt/wt (A&E), 
wt/ko (B&F), ko/wt (C&G), and ko/ko (D&H) shown at 1- and 12-months of age 
respectively. Red/pink stain indicates thicker collagen fibers; blue stain indicates thinner 
collagen fibers, nuclei stain black. Images captured at 40X and oriented with alveolar 
bone on bottom, PDL center, and tooth cementum on top. Bar in A&E=25 µm and 











Overall apparent decreases in stain intensity are visible in ko/ko 1 month PDL 
indicative of overall reduction in collagen content (Fig. 15D). At 12 months of age (Fig. 
15E-H), differences between transgenic mice were not as significant as the 1-month time 
point. Interestingly, the predominant red staining of collagen fibers evident at 1 month in  
wt/ko PDL appears to be reduced at 12 months of age (Fig. 15F). Double-transgenic 
ko/ko 12 month PDL displays loss of red-stained fibers when compared to single 
transgenics; resulting in a PDL consisting primarily of blue-stained collagen fibers (Fig. 
15H).   
Mechanical Strength of PDL 
Reductions in total collagen content and fiber morphology have been reported to 
correlate with decreases in mechanical strength of SPARC-null PDL [66]. Measurements 
of the force required to extract teeth from each genotype at 1 month of age are shown in 
Fig 16. Consistent with previous reports, the force required to extract SPARC-null 
(ko/wt) teeth was significantly decreased compared to WT and exon-2 deleted (wt/ko) 
teeth [137]. Double-null (ko/ko) PDL exhibited further decreases in mechanical strength 
compared to both WT and SPARC-null (ko/wt) PDL (Fig. 16). Unexpectedly, exon-2 
deleted (wt/ko) teeth required greater forces to extract teeth compared to WT (wt/wt) 
despite reduced amounts of total collagen and thick collagen at 1 month of age as 
measured by PSR stain (Fig. 12&14).  
Increases in Fibroblast Proliferation in SPARC-null/exon-2 deleted PDL 
 
 Fibroblasts are the primary cell type that synthesize and secrete collagen in the 













Figure 16. Mechanical force of tooth extraction varies among transgenic PDL. 
Quantification of n=4 mice, 2 replicates/mouse. *p<0.05 compared to wt/wt, #p<0.05 













Figure 17. Ki67 expression is increased in single- and double-transgenic murine 
PDL. Representative images of Ki67 immunohistochemistry localized in sections of PDL 
from wt/wt (A), wt/ko (B), ko/wt (C), and ko/ko (D) 1-month mice. All images are 
oriented with tooth on top, PDL center, and alveolar bone on bottom; 40X magnification. 
Bar in A=100 µm and applies to all panels. (E) Quantification of n=5 mice/genotype, 5 




To detect whether transgenic mice exhibited differences in fibroblast proliferation 
immunohistochemistry, using Ki67 as a marker of proliferating cells, was performed. 
Representative images from each genotype are shown in Fig. 17A-D. Quantification of 
Ki67 positive cells demonstrated a marked increase in proliferating cells in SPARC-null 
(ko/wt) and exon-2 deleted (wt/ko) PDL over that of WT PDL at 1 month (Fig. 17E). 
Increases in Ki67 positive cells were observed in 1-month double-null PDL compared to 
single transgenics or WT PDL. Double antigen labeling using Ki67 and  
vimentin supported that the predominant cell type displaying increases in proliferating 
cells were PDL fibroblasts (Fig. 18).  
Increases in Epithelial Rests of Malassez in SPARC-null/exon-2 deleted PDL 
 
H&E staining of transgenic PDL revealed an increase in the number of rests of 
Malassez in SPARC-null/exon-2 deleted (ko/ko) versus WT (Fig. 19A-D) as well as 
increased size of ERMs (determined by %PDL occupied by ERMs) in 1-month SPARC-
null/exon 2-deleted PDL (ko/ko) compared to single transgenics and WT (Fig. 19J). 
Cytokeratin is present in the periodontium during tooth and PDL development in the 
enamel organ, junctional epithelium, and in rests of Malassez [139]. In adults, the only 
remnants of cytokeratin expression in the PDL are found in the rests of Malassez. 
Immunofluorescence using a pan-cytokeratin antibody confirmed significant increases in 
number of ERMs/PDL section (Fig. 19E-H). At 12 months of age, double-null PDL 
displays expansion of ERMs and PDL area occupied by these rests in comparison to less 
dramatic increases found in WT and SPARC-null PDL (Fig. 19I, J). Interestingly, the 
number and area of the ERMs decreased in PDL of exon-2 deleted mice at 12 months in 












Figure 18. Ki67 and vimentin double antigen labeling supports increases in 
fibroblast proliferation in transgenic PDL. Representative images of Ki67 and 
vimentin immunohistochemistry localized in sections of PDL from wt/wt (A), wt/ko (B), 
ko/wt (C), ko/ko (D) 1-month old mice. Ki67+ cells stained brown and vimentin+ cells 
stained purple. All images are oriented with alveolar bone on bottom, PDL center, and 
tooth cementum on top. Images taken at 40X magnification. Bar in A=50 µm and applies 
to all panels. Black arrows indicate representative cells positive for both Ki67 and 
vimentin. White arrows indicate representative Ki67 positive, vimentin negative cells. 











Figure 19. Number and size of epithelial rests of Malassez (ERMs) varies in murine 
periodontal ligament (PDL). Representative sections from 1 month wt/wt (A), wt/ko 
(B), ko/wt (C), and ko/ko (D) PDL stained with H&E. Black arrows indicate multi-
cellular ERMs. Bar in A=25 µm and applies to all panels. Representative images from 1 
month PDL stained for cytokeratin immunoreactivity (green); wt/wt (E), wt/ko (F), ko/wt 
(G), ko/ko (H). Nuclei stained blue (DAPI). White arrows indicate multi-cellular rests of 
Malassez expressing cytokeratin. Images are representative of n=3 mice/genotype.  I. 
Quantification of average number of rests present in sampled PDL. J. Percent of PDL 






Alterations of Alveolar Bone Volume Fraction in SPARC-null/exon-2 deleted Mandible  
 
To determine whether transgenic mice demonstrated differences in bone density, 
mandibular bone volume fraction (BV/TV) were measured by microcomputed 
tomography (µCT) analysis at 1-month (Fig. 20). Single-transgenic exon-2 deleted  
 (wt/ko) mice displayed decreased levels of alveolar BV/TV when compared to WT 
counterparts. SPARC-null (ko/wt) mice had the highest BVF compared to all genotypes. 
The loss of the N-propeptide in the absence of SPARC (ko/ko) resulted in increased 
alveolar BV/TV compared to both single-transgenic and WT mice (Fig.  20).  
 
Section 2. Ligature-induced PD induces greater loss of periodontal tissues and alters 
monocyte-derived cellular response in SPARC-null mice.   
 Previous reports from our laboratory utilizing an LPS-induced model of PD 
reported reduced inflammatory infiltrate present in SPARC-null PDL compared to WT 
PDL. SPARC-null mice also displayed greater bone loss following LPS challenge 
compared to WT mice, and marked deficits in PDL collagen content and morphology 
versus WT PDL [117]. These results suggested that inherent differences in ECM 
composition are critical for determining PD outcomes. LPS injections are frequently 
critiqued due to the lack of bacterial colonization phase and natural PD progression of 
this model. To extend the results of our previous study we employed a ligature-induced 
model of PD to circumvent the shortcomings of the LPS model. We first aim to validate 
the clinical relevance of the ligature model and to further investigate alterations to PD 




Figure 20. Loss of SPARC or N-propeptide deletion have opposite effects on murine 
alveolar bone volume fraction (BV/TV). Representative µCT images of 1-month mouse 
mandibles (left) from wt/wt (A), wt/ko (B), ko/wt (C), and ko/ko (D). E) Quantification 
of mandibular BV/TV of transgenic mice indicates significant differences in alveolar 
bone volume fraction of both single transgenics and double transgenics when compared 
to wt/wt. n = 8 for each genotype and samples were equally distributed by gender.  





Ligature Model Reduces Alveolar Bone Volume Fraction in Murine Maxillae 
 To best represent natural disease pathogenesis we adopted the ligature-induced 
model of PD, initially described by the laboratory of George Hajishengallis [116], as a 
clinically-relevant model (Fig. 21A). Maxillary alveolar bone volume/total volume 
(BV/TV) was assessed by microcomputed tomography (µCT) analysis at 5- and 14-day 
time points following ligature placement in SPARC-null and WT mice. Significant 
(p<0.05) decreases in alveolar BV/TV in both WT and SPARC-null ligated maxillae 
were used as a clinical hallmark of PD. Significant reductions in alveolar BV/TB in both 
WT and SPARC-null with ligature at the 5-day time point (Fig. 21C). By 14 days, WT 
mice recovered bone volume to levels not significantly different from baseline, whereas 
SPARC-null maxillae had persistent decreases in BV/TV (Fig. 21D).  
Increased Monocyte-Derived Cell Populations Following Ligature are Reduced in 
SPARC-null PDL 
Immunohistochemistry of monocyte-derived F4/80 positive macrophage cell 
populations revealed robust increases following ligature in WT PDL compared to control 
non-ligated PDL (Fig. 22; indicated by arrows). The presence of SPARC-null F4/80+ cell 
populations also increased in PDL following ligature-induced inflammation, but to a 
lesser extent when compared to WT ligature cell populations (Fig. 22).  
Ligature Increases Osteoclast Activity and Alters Distribution in PDL 
Since both macrophages and osteoclasts derive from the same monocyte precursor 
cell, tartrate-resistant acid phosphatase (TRAP) staining was conducted on WT and 
SPARC-null PDL, following 5-day (Fig. 23A & B) and 14-day ligature, to indicate 
multinucleated bone-lining osteoclast cell populations.  
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Figure 21. Ligature model significantly reduces alveolar bone volume fraction. A) 
Ligature in vivo model. B) Representative µCT images of ligature-induced alveolar bone 
loss around second maxillary molar (blue arrows). C) Bone volume/tissue volume 











Figure 22. Ligature increases F4/80+ cell populations in WT and SPARC-null PDL. 
Representative images of F4/80 immunohistochemistry of WT and SPARC-null PDL +/- 
following 5-day ligature. Blue arrows indicate characteristic F4/80+ cells. Images 






































Quantification of TRAP+ cell populations revealed significant increases following 
ligature of WT PDL at both 5- and 14-day time points (Fig 23C & D). Recapitulating the 
F4/80 IHC (Fig. 22), SPARC-null PDL also exhibited increased TRAP+ staining 
following ligature at 5-day time point versus control but the response was muted 
compared to WT PDL at day 5 (Fig. 23C). Interestingly, SPARC-null TRAP+ staining 
was not significantly different following 14-day ligature compared to control (Fig. 23D). 
Distribution of TRAP+ cells increased in both WT and SPARC-null PDL, decreased in 
WT bone lacunae, and decreased at the SPARC-null PDL:bone interface at 5-days (Fig 
23D). Following 14-day ligature WT TRAP+ increased at PDL:bone interface and 
decreased in alveolar bone lacunae; no significant changes detected in SPARC-null 
TRAP+ distribution at this time point (Fig. 23E & F).       
Ligature-Induced Changes in Monocyte Cell Populations not Attributed to Inherent 
Differences in Hematopoietic Cell Lineages of WT and SPARC-null Mice 
To assess potential inherent differences in hematopoietic lineages that could 
contribute to differences in macrophage and/or osteoclast cell populations, flow 
cytometric analysis was conducted on peripheral blood of WT (Fig. 24C) and SPARC-
null mice (Fig. 24D). Gender differences between male and female mice of both 
genotypes were assessed. Experiment was replicated in triplicate to confirm results. We 
report no inherent differences in the circulating hematopoietic cell lineages between WT 
and SPARC-null mice (male and female). These results indicate that differences observed 
between WT and SPARC-null inflammatory infiltrate in PDL following PD are not due 





Figure 23. Ligature aberrantly affects TRAP+ cell populations in WT and SPARC-
null PDL at 5- and 14-day time points. A) TRAP staining in WT and SPARC-null PDL 
5-day ligature, 4X magnification, scale bar = 100µm and B) 40X magnification, scale bar 
= 25µm. C) & D) Average number of TRAP+ cells at 5- and 14-day time points, 
respectively. E) TRAP+ cell distribution at 5-day, p*<0.05 vs. control, #p<0.05 vs. WT, 
and F) 14-day time points.*p<0.01 vs. control. SPARC-null displayed no significant 
differences compared to control or WT. n=3, 5sections/mouse for all quantification.  
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Figure 24. Hematopoetic cell lineages do not differ between WT and SPARC-null 
mice. A) Representative example of gating and B) isotype controls used for flow 
cytometric analysis. C) Representative flow cytometric analysis showing percent of WT 
and D) SPARC-null peripheral blood cells positive for CD8 and CD4 (top right panel), 
cell populations positive for Mac1 and Gr1 (bottom left panel) and those positive for 






Osteoblast Populations Unchanged in SPARC-null PDL Following Ligature    
Changes to osteoclast cell populations are sometimes attributed to alterations in 
the osteoclast:osteoblast coupling events that take place during bone homeostasis and 
turnover. Alkaline phosphatase (ALP), a marker of osteoblast activity, was used to 
conduct immunohistochemistry on WT and SPARC-null PDL following 5-day ligature 
treatment. WT control PDL displayed an unexpected high level of ALP expression, 
which decreased following 5-day ligature (Fig. 25). SPARC-null PDL revealed decreased 
ALP expression when compared to WT, which did not significantly change following 5-
day ligature treatment (Fig. 25B). 
SPARC-null PDL Collagen Content is Reduced in Ligature Model  
 Picro Sirius red (PSR) histological staining of WT and SPARC-null PDL (Fig. 
26A) with and without ligature (5- and 14-day time points) visualized under polarized 
light was conducted and quantified by morphometric analysis. Total collagen I content of 
both WT and SPARC-null PDL had significant reductions following 5-day ligature 
compared to controls (Fig. 26B). SPARC-null control PDL demonstrated significantly 
less total collagen content compared to WT control, reflective of our previous reports 
(Fig. 26B,C). Following trends observed in bone (Fig. 26D), WT PDL collagen content 
recovered to non-significant levels with 14-day ligature whereas SPARC-null PDL did 
not (Fig. 26C). Thin collagen fibers of WT PDL, differentiated by green/orange 
birefringence increased following ligature at both time points (Fig. 26E, F). High levels 
of thin collagen fibers in SPARC-null PDL remained constant following ligature at both 




Figure 25. Alkaline phosphatase expression is unchanged in the absence of SPARC. 
A) Representative IHC images of WT (+/+) and SPARC-null (-/-) control and 5-day 
ligature treated PDL following staining for alkaline phosphatase expression (brown 
precipitate). Scale bar in top left panel = 25µm and applies to all panels. B) 
Quantification of ALP expression. n=5 mice, 5 sections/mouse. #p<0.05 vs. control. 














Figure 26. SPARC-null PDL collagen content and fiber diameter are further 
reduced in ligature model compared to WT. A) Representative Picro Sirius Red (PSR) 
images of WT and SPARC-null PDL following 5-day ligature. B) Quantification of total 
collagen I content of PDL following 5-day and C) 14-day ligature. D) Representative 
images of Herovici-stained WT and SPARC-null PDL following 5-day ligature. E) 
Quantification of thin collagen fibers (green/yellow) from PSR images following 5-day 
and F) 14-day ligature. Scale bar in A and D = 25µm and applies to all panels. n=5 








Herovici histological stain easily differentiates thin (blue) versus thick (pink/red) 
collagen fibers of WT and SPARC-null PDL and validates PSR findings (Fig. 26D). 
SPARC-null Native PDL Exhibits Disorganized Three-Dimensional Collagen 
Morphology  
 Second-Harmonic Generation (SHG) microscopy is used to detecting three-
dimensional biological structures with high hyperpolarizability, like collagen fibers, in 
fresh, non-fixed, non-decalcified, tissue samples. SHG microscopy was utilized to 
highlight the morphology of PDL collagen fibers with high resolution and contrast (Fig. 
27). Backward-emitted SHG imaging was conducted on fresh WT and SPARC-null 
homeostatic PDL. Native SPARC-null PDL exhibits disorganized, thinner collagen fibers 
compared to WT PDL (Fig. 27).   
 
Section 3. TG controls collagen cross-links in PD. 
 The reductions in alveolar bone volume and PDL collagen content and 
morphology in SPARC-null mice compared to WT mice suggested the importance of 
ECM assembly, composition, and remodeling during PD. While we know SPARC 
facilitates collagen assembly in the PDL during homeostasis and PD the mechanism 
behind collagen fiber morphology is unknown. Previously, our lab has shown in 
homeostatic PDL that inhibition of the cross-linking enzyme TG2 has partially rescued 
SPARC-null collagen content and thickness, which translated functionally to increased 
mechanical strength of the PDL. Herein we propose a mechanistic function of TG in 











Figure 27. Three-dimensional SPARC-null PDL collagen fibers exhibit disorganized 
morphology. SHG images acquired with longitudinal sectioning of fresh, homeostatic 
WT and SPARC-null PDL (age: 3 months). Images taken with 30X objective lens, zoom 
2, and oriented with tooth on top, PDL centered, alveolar bone on bottom. Red pixel 
coloration indicates laser saturation of collagen-rich surrounding tissues (tooth and bone) 












Increased TG2 Activity in PDL in the Absence of SPARC   
 Inhibition of TG in vivo partially restores mechanical strength of SPARC-null 
PDL collagen fibers during homeostasis. To test the expression and cross-links mediated 
by TG2 during inflammatory PD, immunohistochemistry was conducted in WT and 
SPARC-null PDL following ligature treatment (5- and 14-day time points). Consistent 
with increases in TG2 expression observed during other inflammatory disease states, TG2 
expression significantly increases in both WT and SPARC-null PDL following 5-day 
ligature compared to control PDL (Fig. 28A). WT and SPARC-null ligated PDL exhibit 
similar increases in TG2 expression (Fig. 28A). Using an antibody directed against the 
TG2 cross-link epitope, IHC revealed significant increases in TG-mediated cross-links in 
ligated (5-day) WT PDL compared to control PDL. TG2-mediated cross-links increase 
significantly further in ligated (5-day) SPARC-null PDL compared to ligated WT PDL 
and controls (Fig. 28B). WT and SPARC-null PDL, following 14-day ligature, display 
similar trends of increasing TG2 expression; only WT PDL shows statistically significant 
increases (Fig. 28C). IHC of 14-day ligature-treated PDL reveal increases in TG2-
mediated cross-links in both WT and SPARC-null (Fig. 28D), recapitulating 5-day data.      
TG and SPARC Protein Expressed in Human PDL Fibroblasts  
 Aberrant changes in TG2 and SPARC expression levels have been reported in 
inflammatory disease states. To analyze TG2 and SPARC protein expression levels in 
patients, human PDL (hPDL) fibroblasts were obtained from healthy and diseased (PD) 
participants. hPDL fibroblasts were cultured to passage 5 and then collected for 
immunoblotting. Protein extracted from hPDL fibroblasts of patient #5 (PD) and patient 
#9 (healthy control) expressed both TG2 and SPARC (Fig. 29).  
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Figure 28. Ligature increases TG2 expression in SPARC-null and WT PDL. TG 
activity increases in ligature model in the absence of SPARC. A) Representative IHC 
images of anti-TG2 following 5-day ligature; quantification of positive TG2 staining 
graphed below. Scale bar: 30µm and applies to all panels. B) Representative IHC images 
of anti-N-ε-γ-glutamyl lysine following 5-day ligature; quantification of positive cross-
linking epitope staining shown below. N=5. C) Quantification of positive TG2 and D) 
TG cross-linking epitope staining following 14-day ligature.  N=3. *p<0.05 vs. control. 




Figure 29. Human PDL Fibroblasts Express TG2 and SPARC Protein. Western blot 
for TG2 and SPARC protein in human PDL fibroblasts obtained from 1 healthy patient 



















In these preliminary experiments, apparent increases in expression levels of TG2 and 
SPARC are observed in hPDL fibroblasts from patient #5 suffering from PD compared to 
patient #9 healthy control patient (Fig. 29). Coomassie blue staining was used for equal 
loading of protein. B-tubulin was used as a housekeeping gene.  
Inhibition of TG Decreases Alveolar Bone Volume Fraction Following Ligature  
Following TG inhibition by BC injections (or DMSO vehicle control) for 4 days 
followed by 24 hours in organ culture WT C57Bl/6 mice, maxillae were dissected and 
alveolar bone volume fraction (BV/TV) was analyzed by µCT. Five-day ligature induced 
significant reductions in BV/TV of maxilla in both vehicle and BC-treated groups (Fig. 
30B). Interestingly, mice with ligature receiving daily injections of BC for TG inhibition 
demonstrated further reductions in alveolar BV/TV compared to vehicle DMSO-injected 
maxillae (Fig. 30B). Qualitative BV/TV reductions are not patently discernable despite 
representative images (Fig. 30A) taken from samples exhibiting the greatest deviations in 
BV/TV from the mean. 
Inhibition of TG Restores PDL Collagen Content Following Ligature  
 Collagen fiber morphology and content of WT PDL, with and without ligature, 
+/- TG inhibition with BC injections is visualized by PSR staining and Herovici staining 
protocols. Red/orange polarized PSR is indicative of thick collagen fibers, while 
yellow/green polarized PSR indicates thin collagen fibers (Fig. 31A). Five-day ligature 
treatment significantly reduces total collagen content of PDL in both DMSO and BC-
treated mice. BC injections increase total collagen content in both control and ligature-
treated PDL compared to DMSO injected counterparts (Fig. 31C).  
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Figure 30. TG inhibition induces further reductions of BV/TV following 5-day 
ligature compared to vehicle. A) Representative µCT images of DMSO or BC-injected 
WT maxillae following 5-day ligature or control. B) Quantification of bone volume/total 
volume (BV/TV) of WT maxillary alveolar bone for each treatment group. N=5 














Figure 31. Injection of BC increases total PDL collagen content by rescuing thick 
and thin fibers following ligature. A) Representative polarized PSR-stained PDL 
sections of WT mice with and without 5-day ligature +/-BC injections. Scale bar: 25um, 
applies to all panels. B) Representative Herovici-stained PDL images. Pink/red = 
thick/mature collagen fibers, blue/purple = thin/young collagen, yellow = reticulum/cell 
death, black = nuclei. All images oriented with tooth on top, PDL center, and alveolar 
bone on bottom. All ligature images taken of PDL surrounding ligated 2nd maxillary 
molar. 40X magnification. C) PSR quantification percent total collagen. D) PSR 
quantification thick vs. thin collagen fibers. N=5 mice/group, 5 sections/mouse. *p<0.05 
vs. control. #p<0.05 vs. DMSO.  
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Ligature treatment reduces percent of thin and thick fibers in both DMSO and BC-
injected PDL (Fig. 31D). Interestingly, BC-injections increased both thin and thick 
collagen fibers following ligature when compared to DMSO-injected PDL (Fig. 31D). 
BC-injections even significantly increased thick collagen fiber content of control un-
ligated PDL compared to DMSO-injected control PDL (Fig. 31D). Herovici-stained PDL 
validated collagen finding reported by PSR. Herovici stains thick/mature collagen 
pink/red, thin/young collagen blue/purple, reticulum/cell death yellow, and nuclei black. 
DMSO injections induce reductions in pink thick fibers, reductions in blue thin fibers, 
and increases in yellow staining indicative of cell death in both control and ligated PDL 
compared to BC-injected PDL (Fig. 31B, top two panels). Herovici staining of BC-
injected PDL reveals increases in both thick and thin (pink and blue, respectively) 
collagen fibers, and reduced cell death (yellow) compared to DMSO-injected PDL (Fig. 
31B, bottom two panels). BC-injected 5-day ligature treatment induces apparent minor 
reductions in thick and thin fibers as well as slight increases in cell death (yellow) 
compared to control BC PDL (Fig. 31B, right panel). 
Inhibition of TG Rescues Collagen Morphology in Native PDL Following Ligature   
 Second-harmonic generation imaging enables the visualization of native PDL 
collagen in 3-dimension. Orthogonal reconstruction of z-stacked images taken of murine 
PDL +/- BC/DMSO injections following 5-day ligature provide qualitative data on 
collagen morphology, organization, and fiber bundle thickness in WT mice (Fig. 32). 
DMSO-injection alone induced morphological changes in collagen organization of PDL.  
Five-day ligature further degrades PDL collagen fiber morphology and reduces 
discernible thick fiber bundles. 
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Figure 32. BC injection rescues collagen fiber morphology in native WT PDL 
following ligature treatment. Representative second-harmonic generation orthogonal 
images generated from z-stacks taken at 0.2µm/slice for depths of up to 60µm of native 
WT PDL +/- BC/DMSO injections following 5-day ligature treatment. Apparent 
increases in collagen fiber thickness and organization are observable in BC-treated PDL 
compared to DMSO-treated PDL. Following ligature, reappearance of thick collagen 
fiber bundles are apparent in BC-treated PDL compared to DMSO-treated PDL.  





BC-injection alone increases apparent collagen fiber thickness and total content in PDL 
when compared to DMSO control. Additionally, the presence of thick collagen bundles 
reappear following 5-day ligature treatment with addition of BC injection (Fig. 32).    
Inhibition of TG Increases Native PDL Collagen Organization 
 To quantify backward SHG imaging, two-dimensional compilations of z-stack 
images (Fig. 33A) were subjected to Fourier transformation, based on intensity, to 
retrieve the pattern of image line directions, so as to characterize the geometry of the 
image texture. The frequency distribution in a Fourier-transformed (FFT) imaged was 
quantitatively calculated by fitting the result with an ellipse and by calculating the ratio 
between its short and long axes, i.e. its aspect ratio (AR) (Fig. 33B). The 2D FFT 
diagrams transform from circular shapes to elliptical shapes, which indicates a transition 
from random patterns to organized patterns (Fig. 33B, top to bottom). The increase of the 
corresponding AR is evident when moving from DMSO-treated to BC-treated PDL (Fig. 
33C). It is noteworthy to emphasize the capacity of the AR to reveal transitions from 
more disorganized patterns (DMSO-treated PDL) to more normal or structured patterns 
(BC-treated PDL). Quantification of AR for WT (no treatment, no injection), DMSO +/-
ligature, and BC +/-ligature are represented in Fig. 33D.  
Inhibition of TG Restores Mechanical Strength of PDL Following Ligature  
 Previous differences in homeostatic PDL total collagen and thick fiber content 
have translated to corresponding variations in mechanical strength (Fig. 16). The partial 
rescue of PDL collagen content following disease induction by inhibition of TG is 

















Figure 33. Second-harmonic generation reveals increased PDL collagen fiber 
organization following inhibition of TG. A) Representative stack of SHG images 
(1024x1024 µm2 ROIs) taken from PDL of WT mice +/-BC/DMSO-injections following 
5-day ligature. B) The FFT diagram of each representative ROI C) The calculated value 
of the aspect ration (AR) of the ellipse approximating the FFT magnitude of 
representative ROIs D) Graph of the mean value (+/-SD) of the aspect ration (AR) of all 
4 groups with the addition of mean WT (no injection, no ligature) values for comparison. 
N=6/group, *p<0.01 vs. control, #p<0.01 vs. DMSO, $p<0.01 vs. WT. No statistical 
differences are reported between WT and BC control means.      
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Indeed, BC-injected PDL following ligature demonstrated significant increases in the 
maximum force withstood prior to tooth extraction compared to DMSO-injected PDL 
following ligature (Fig. 34, black bars). Wild type and DMSO/BC control PDL without 
ligature all withstood a maximum force of 5.5 newtons prior to wire failure. Therefore 
differences in increased strengths between control groups are not reported and no 
statistical analysis was conducted, merely the maximum force withstood by the wire is 


























Figure 34. BC increases mechanical strength of PDL following ligature. 
Quantification of maximum force withstood by PDL prior to tooth extraction (black bars) 
or apparatus wire failure (white bars). N=5 mice/group, *p<0.05 compared to control, 



























































Section 1. SPARC and the N-propeptide of collagen I influence fibroblast 
proliferation and collagen assembly in the PDL.  
These results evaluated whether the N-propeptide of collagen I influences ECM 
assembly and fibroblast proliferation in the PDL and if loss of the N-propeptide in 
combination with loss of SPARC expression further exacerbates the defects in PDL 
collagen characteristic of SPARC-null PDL. Collagen content and fiber morphology in 
the PDL of exon 2-deleted and double-null mice were significantly compromised, with 
double-null mice demonstrating the most significant loss of collagen at 3 months of age 
(Fig. 12E and 14). The force required to extract teeth at 1 month of age was also lowest in 
double-null mice versus that of either single transgenic or WT mice, indicating that the 
loss of collagen content and integrity directly correlated to a decrease in mechanical 
stability of the PDL (Fig. 16). Fibroblast proliferation and the number of rests of 
Malassez were increased in SPARC-null and exon 2-deleted PDL with the greatest 
elevations observed again in double-null PDL compared to WT PDL (Fig. 17 and 19, 
respectively). Interestingly, exon-2 deleted mice demonstrated the highest level of force 
required for molar extraction at 1 month of age despite reductions in collagen and thick 
fiber content reported by PSR (Fig. 16). Differences in PDL collagen characterized herein 
for exon-2 deleted mice are the first phenotypic alterations reported for these mice and 
thus demonstrate functional significance for the N-propeptide in collagen fiber formation 
in vivo.  
The function of the N-propeptide in collagen biology is not well defined [140]. 
Mutations found in patients that either reduce or prevent processing of the N-propeptide 
from collagen I give rise to malformed collagen fibrils and weaker tissue strength. 
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Dermatosporaxis is a disease associated with inefficiency in processing of the N-
propeptide of collagen I due to reduced or abrogated enzymatic activity of the N-
propeptide proteinase, ADAMTS2/3 and 14, that gives rise to fragile skin among other 
pathologies [141]. Clearly, retention of the N-propeptide of collagen I is detrimental to 
collagen fiber assembly and tissue formation and is presumably mediated by interference 
of the retained N-propeptide in collagen fibrils. Studies carried out in cultured cells 
suggested that the N-propeptide might act as a feedback inhibitor of collagen production 
[142]. As such, mice lacking the N-propeptide were anticipated to demonstrate increases 
in collagen content brought about by the lack of this inhibitory function. The exon 2-
deleted mice were originally generated to test this hypothesis. 
Bornstein et al. reported that exon 2-deleted mice lacked an overt collagen 
phenotype characterized primarily at 2 months of age in skin, although there was some 
embryonic lethality on specific backgrounds [136]. Similarly, our laboratory reported a 
lack of phenotypic differences in adult skin of exon-2 deleted mice [135]. However, 
when coupled with a lack of SPARC expression, robust differences in dermal collagen 
content and morphology were found in SPARC-null/exon-2 deleted mice over and above 
that of SPARC-null mice, perhaps suggesting a cooperative role of SPARC and N-
propeptide. In contrast to skin, at 1 month of age the PDL of exon-2 deleted mice 
displayed decreased total collagen and increases in thin fibers (Fig. 12E and 14). 
Interestingly, this collagen phenotype appeared to recover in the exon-2 deleted PDL by 
the 12-month age point. Perhaps, a compensatory mechanism supported by other 
collagens present in the PDL of exon-2 deleted mice mediates recovery. In addition to 
type I, type III collagen is highly expressed by human gingival and PDL fibroblasts 
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[143]. The N-propeptide of procollagen III is synthesized in a very comparable pattern to 
that of procollagen I and has similarities in sequence and structure to the N-propeptide of 
collagen I [144]. Hence, functional redundancy of the N-propeptide of procollagen III 
might compensate for the lack of the type I N-propeptide in the exon-2 deleted mouse 
and explain the collagen I phenotypic recovery observed in these mice at later time 
points. We also speculate that the high rate of collagen turnover in the PDL affords the 
opportunity to discern functional activities of the N-propeptide that might be more subtle 
in tissues with slower collagen turnover such as the skin.  
Few published reports characterizing collagen fiber analysis by Herovici stain are 
available. Reynolds et al. reported that collagen fibers, when treated with collagenase, 
undergo changes in Herovici stain color from red to blue. In addition, tissues with higher 
levels of thin collagen fibers, such as embryonic and those with healing wounds, 
demonstrate increases in blue stained collagen fibers over red fibers [145]. In our hands, 
differences in blue and red-stained fibers are evident in 1- and 12-month murine PDL. 
Particularly, the exon-2 deleted 1 month PDL (Fig. 15B) that displays an apparent 
increase in red-stained fibers, compared to WT, that can be observed weaving into tooth 
and bone. Herovici staining might provide an improved method for visualizing thin 
collagen fibers, particularly in the PDL, versus PSR because of the inherent strong PSR 
signal from surrounding collagen rich tissues (bone and tooth). In contrast to other soft 
tissues, not surrounded by collagen-rich mineralized tissues, the distinction between thick 
and thin collagen fibers in the PDL can be challenging by PSR histology. An increase in 
thick collagen fibers in exon-2 deleted mice visualized with Herovici stain would be 
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consistent with increases in mechanical strength observed in these mice at a month of 
age.  
At 1 month of age, the mechanical strength of the double transgenic SPARC-
null/exon-2 deleted PDL was significantly decreased compared to all other genotypes as 
evidenced by the decrease in force required for molar extraction (Fig. 16). This result is 
in line with the decreased collagen content and fiber thickness observed histologically. 
The exon-2 deleted mice were the only transgenic line studied that displayed increased 
mechanical strength of PDL compared to WT, a surprising result based on the reduced 
amount of collagen I observed at 1 month versus WT mice. A possible explanation is that 
subtle differences in collagen structure might exist in the exon-2 deleted PDL that 
account for increases in strength of the ECM in the absence of overt differences in 
collagen fiber morphology or content. For example, changes in ECM structural properties 
originating from alterations to collagen cross-linking could contribute to the increased 
mechanical strength of the PDL observed in exon-2 deleted mice. Future experiments to 
understand how ECM composition might alter mechanical properties of the PDL should 
be enlightening.   
Fibroblast proliferation, as measured by Ki67 positive cells, was increased in the 
PDL of both single-transgenic mice. The increase in proliferation was further exaggerated 
in double-null PDL compared to single transgenics and WT (Fig. 17 and 18). Fibroblasts 
are known to bind and respond to growth factors sequestered in the matrix, particularly 
during wound healing [146]. In an ECM environment characterized by decreased 
collagen content such as that of the transgenic mice, factors normally sequestered, for 
example fibroblast growth factor-2 (FGF-2), might be present in higher concentrations as 
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active, soluble factors that stimulate fibroblast proliferation versus WT PDL. Perhaps the 
increase in fibroblast proliferation might represent a compensatory mechanism to 
replenish the lack of collagen content in double-null PDL, for example. 
Epithelial Rests of Malassez (ERMs) were also increased in the PDL of transgenic 
mice (Fig. 19). ERMs are cell clusters from Hertwig’s epithelial root sheath (HERS) that 
remain in the PDL after root formation is complete. ERMs are known to proliferate and 
increase in size under conditions of PDL stress, such as orthodontic tooth movement, but 
their functional role in the ECM is poorly understood [147]. ERMs are capable of 
undergoing epithelial-mesenchymal transition and differentiate into various cell types 
[148]. These cell rests are speculated to play a role in regeneration and repair of the 
periodontium. The increase in number and area of these rests observed in single-
transgenic mice and further exaggerated in double-transgenic mice could serve as an 
indicator of a stressed and weakened PDL. As each of these transgenic mice displayed 
decreases in thick collagen and increases in thin collagen, one might speculate that each 
also has increased tooth movement during mastication. The increases in tooth movement 
resulting from a weaker PDL might explain the increase in ERMs observed in transgenic 
mice when compared to WT. ERMs are also known to proliferate with age in homeostatic 
murine PDL [149]. Cell adhesion and proliferation potentially contribute to epithelial cell 
rest proliferation and growth within the PDL matrix. However, Yan et al. reported no 
differences in lens epithelial cell proliferation in the absence of SPARC compared to WT 
in vivo [150]. Since the absence of SPARC does not affect epithelial proliferation 
globally, we do not highlight epithelial cell expansion as a main factor altering the ERM-
matrix structure.  The increased presence of ERMs in 12-month WT PDL is attributed to 
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aging PDL turnover and remodeling. The significant increase in SPARC-null rests at 12 
months compared to WT correlates with the decrease in total collagen content (Fig. 12E) 
and a decrease in the amount of thick fibers present in 12-month PDL (Fig. 14). We 
hypothesize the failure of SPARC-null PDL to recover collagen content at 12-months 
indicates a stressful/weakened ECM resulting in further ERM proliferation. Interestingly 
the recovery of the collagen phenotype observed in exon-2 deleted PDL at 12 months 
(Fig. 12E  and 14) is reflected in a decrease in the number and area of ERMs occupying 
the PDL at this age. Double-null PDL at 12 months, was shown to have substantial 
decreases in collagen content and morphology likely resulting in a robust proliferation of 
both number and size of ERMs (Fig. 19I and J).  
Surprisingly, the BV/TV of exon-2 deleted mandibles was the lowest of all 4 
genotypes tested whereas SPARC-null single transgenics had increased BV/TV at 1 
month of age versus wt/wt (Fig. 20E). Previously, our laboratory reported reductions in 
mandibular BV/TV at 4 months in SPARC-null mice consistent with overall reductions in 
SPARC-null mice characteristic of an osteopenic phenotype [67, 117]. These results 
indicate that the absence of SPARC expression does not primarily influence bone 
deposition during mandible development but is required for bone maintenance over time, 
in line with studies from other types of bone in SPARC-null mice [77]. The fact that 
exon-2 deleted mandibular bone demonstrated significant decreases (Fig. 20E) compared 
to other genotypes suggests a role of the N-propeptide in bone development, the 
mechanism of which will be the subject of future studies. Possibly, expression or 
localization of other ECM proteins known to participate in calcification of bone matrix, 
such as osteopontin, might be altered in exon-2 deleted mice. 
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We conclude that the absence of SPARC expression combined with a lack of the 
N-terminal propeptide exon 2 altered collagen type I morphology, cellularity, and 
mechanical stability of the PDL. The mechanisms behind the activities of both SPARC 
and the N-propeptide of collagen I need further exploration and could provide insight into 
collagen assembly and ECM remodeling. Further studies will highlight potential targets 
in the pathway of collagen assembly and regeneration, applicable to tissues suffering 

















Section 2. Ligature-induced PD induces greater loss of periodontal tissues and alters 
monocyte-derived cellular response in SPARC-null mice.   
Previous characterization of SPARC-null PDL in response to lipopolysaccharide 
injection revealed deficiencies in total collagen volume fraction and collagen fiber 
thickness. Alveolar bone loss associated with LPS injections was greatly increased in the 
absence of SPARC [117]. Since LPS injection is criticized as a model of PD for the lack 
of bacterial colonization and allowance for natural disease progression, we implemented 
a ligature-induced model of PD to assess the role of SPARC on collagen catabolism, 
alveolar bone turnover, and monocyte-derived cellular response to inflammation over 
time. Alveolar bone loss associated with ligature-induced PD increased in SPARC-null 
mice in comparison with WT mice after 5 days (Fig. 21C). Following a longer 14-day 
ligature disease model, reductions in alveolar bone volume were non-significant in WT 
mice, whereas SPARC-null reductions persisted (Fig. 21D). The increased loss of bone in 
SPARC-null mice was not surprising, since these mice develop osteopenia characterized 
by decreased bone mineral density in long bones [67]. Interestingly, the persistent 
reductions in SPARC-null alveolar bone at the 14-day time point suggest contributory 
factors of intrinsic differences in ECM in determining PD outcomes.  
In addition to reductions in mineralized periodontium, decreases in fibrillar PDL 
collagen were reported in SPARC-null mice at 5- and 14-day ligature time points (Fig. 
26). Consistent with alveolar bone volume increases following 14-day ligature, WT PDL 
total collagen content returned to baseline levels (Fig. 26C and F). We attribute the 
increased collagen content to significant increases in thin, newly formed fibers consistent 
with a remodeling matrix. We attribute the absence of an increase in thin fiber content in 
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SPARC-null PDL largely to the inherently higher thin fiber content composition of PDL 
during homeostasis, characteristic of SPARC-null mice. Deficiencies in dermal 
procollagen processing and decreased collagen deposition in ECM have been reported in 
SPARC-null mice [55, 151]. Additionally, high expression levels of SPARC are 
correlated with states of matrix remodeling and tissue turnover such as developing 
embryonic tissues, would healing, and fibrotic disease conditions [41, 152, 153]. Thus, 
the reductions in collagen content in SPARC-null PDL might result from deficient 
collagen deposition in response to the ECM remodeling that occurs following injury.   
Previous reports from our laboratory have described general reductions in 
inflammatory cells following LPS challenge in SPARC-null PDL [117]. Importantly, we 
observed no differences in circulating inflammatory cells in SPARC-null mice (Fig. 24), 
suggesting that recruitment or persistence of macrophages in tissue was dependent on 
SPARC rather than hematopoietic events. Ligature-induced PD resulted in robust 
expression of F4/80+ macrophages in WT PDL with a muted expression in SPARC-null 
PDL (Fig. 22). Macrophages, unlike neutrophils, are known to express SPARC, which 
aids in endothelial extravasation [152]. Again, we report increased persistent 
inflammation in SPARC-null PDL with a reduced number of macrophages present (Fig. 
22). The alterations in ECM in SPARC-null PDL could be limiting macrophage 
recruitment to the area of disease induction. An alternative hypothesis is that although 
there are reduced numbers of macrophages present, these could be more potent matrix-
degrading macrophages versus more matrix-repairing macrophages observed in WT 
PDL. Further investigation into macrophage polarization and/or recruitment in SPARC-
null inflammatory states could elucidate mechanisms specific to SPARC-null 
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macrophages that differ from WT. Reports of SPARC-null mice with dextran sodium 
sulfate (DSS) induced colonic inflammation also demonstrated reduced levels of 
monocytes, neutrophils, and macrophages at the site of inflammation when compared to 
WT mice [154]. However, a study conducted in SPARC-null dermal inflammation 
reported opposite results wherein the mice demonstrated increased inflammatory cell 
movement and recruitment through the looser collagenous ECM of SPARC-null mice 
compared to WT mice [155]. Therefore, the implications of SPARC during inflammation 
appear to be tissue-specific.         
 Since macrophages and osteoclasts derive from the same monocyte precursor cell, 
the outcomes from our TRAP-staining were not surprising, as they recapitulated our 
F4/80+ macrophage results (Fig. 23). Interestingly, the fewer osteoclasts observed in 
SPARC-null mice is counterintuitive to the reductions in bone volume compared to WT 
mice characterized by robust osteoclast staining. Characterization of the SPARC-null 
osteopenic phenotype reported inherent reductions in osteoclast and osteoblast number 
and surface area. Of particular interest was the variation in distribution of the TRAP+ 
osteoclasts. Following 5-day ligature treatment, both WT and SPARC-null mice had 
significant increases in TRAP+ cells present in the PDL itself, not in contact with bone or 
tooth. Osteoclasts at the classic location of bone:PDL interface were reduced only in 
SPARC-null mice (Fig. 23E). By the 14-day time point the numbers of TRAP+ 
osteoclasts were greatly reduced compared to the 5-day time point in both WT and 
SPARC-null mice (Fig. 23D). The distribution of these osteoclasts were unchanged in 
SPARC-null mice following ligature, compared to control and compared to WT 
osteoclast distribution (Fig. 23F). The change in osteoclast number and distribution after 
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a longer state of inflammation at the 14-day time point compared to results of the 5-day 
ligature time point, suggests differences in the healing response of SPARC-null 
periodontium compared to WT periodontium. One study conducted a longer ligature 
time-course utilizing additional time-points of: 3-, 7-, 11-, 15-, and 21-days of ligature in 
male Wistar rats followed by µCT analysis of alveolar bone volume fraction at each time 
point. Rats were reported to have maximum alveolar bone loss at the 11-day time point 
following ligature treatment. By 21 days of ligature, the alveolar bone volume of rats 
returned to non-significant levels compared to control alveolar bone (no ligature 
treatment). The study correlated levels of alveolar bone loss directly with temporal 
expression of matrix metalloproteinases 8 and 13, both of which are found in human 
gingiva and crevicular fluid during PD. Specifically, MMP-13 immunoreactivity was 
localized in an increased number of osteoclasts from day 7 to day 11 of ligature treatment 
[156]. However, there are many additional MMP family members (1, 2, 3, 7, 9, and 10) 
with ECM substrates that are associated with PD outcomes in human patients [157]. 
Specifically, increased levels of MMP-2, -3, and -9 have been reported in epidermal, 
cardiac, and ocular tissues of SPARC-null mice compared to WT mice, respectively [154, 
158, 159]. A longer experimental ligature time course and characterization of the MMP 
profile in periodontal tissues (PDL and alveolar bone) could provide further insight into 
mechanistic differences contributing to osteoclast variation between WT and SPARC-
null mice.      
One theory in PDL biology focuses on the potential of the PDL to house resident 
mesenchymal stem cell populations. These “PDL stem cells” are thought to be capable of 
differentiating toward macrophage/osteoclast cell types and aiding in regeneration of 
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periodontal tissues [160]. Studies have shown that under orthodontic tooth movement, 
during which the PDL is under a state of increased mechanical tension and ECM 
remodeling, that these “PDL stem cells” produce hydrogen sulfide (H2S) which induces 
secretion of monocyte chemoattractant protein-1 (MCP-1) and expression of receptor 
activator of nuclear factor-κB ligand/osteoprotegerin (RANKL/OPG) system. The 
secretion and expression of these factors was directly implicated in macrophage 
migration and osteoclast differentiation and led to differences in regulating the rate of 
alveolar bone turnover [161]. SPARC-null mice have no detectible differences in the 
number of stem cell populations compared to WT mice, only differences in the 
capabilities of these cells to differentiate towards various cell types [75]. However, 
intrinsic differences in SPARC-null ECM could affect the ability of these “PDL stem 
cells” to differentiate and/or migrate towards the alveolar bone, particularly since the 
ligature model increased the numbers of osteoclasts embedded in the PDL and reduced 
the numbers in contact with the ruffled border of the alveolar bone compared to the 
location of WT osteoclasts. Further characterization of differences in cytokine profiles of 
SPARC-null and WT mice in response to ligature-induced inflammation will provide key 
insight into specific mechanisms altering the macrophage and osteoclast response in the 
periodontium.         
 The high expression level of alkaline phosphatase (ALP) observed in the PDL of 
WT control mice was not surprising since PDL cells in vitro have been shown to possess 
high constitutive levels of ALP activity (Fig. 25). Osteoblasts have been reported to 
express large amounts of ALP, that contribute to osteoblast differentiation, when 
stimulated by bone morphogenic protein-2 (BMP-2) in human PDL (hPDL) cells grown 
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in vitro [162]. Current literature lacks reports of ALP expression variations in SPARC-
null compared to WT expression levels. Again, we know from the osteopenic phenotype 
characterization in SPARC-null long bones that, in addition to reductions in osteoclast 
cell numbers and surface area, these mice also exhibit reductions in osteoblast cell 
number and surface area [67]. The osteopenic propensity of SPARC-null cranial bones 
has yet to be reported, but it would be logical to expect similar reductions of OBs and 
OCs as seen in the long bones. Since the reduced levels of ALP expression in SPARC-
null PDL did not change following 5-day ligature, we chose not to focus on the osteoblast 
cell type in determining PD outcomes in our model. Thus, we did not conduct ALP 
staining on samples from the 14-day ligature time point. No significant differences in 
mRNA expression of other markers of osteoblast differentiation: osteocalcin (OCN) and 
osteopontin (OPN), were reported in SPARC-null long bones compared to WT RNA 
levels [67]. Future characterization of mRNA and protein levels of osteoblast-associated 
markers (ALP, OCN, OPN, and osterix) in SPARC-null periodontium will help to 
corroborate the altered PD phenotype reported in our ligature model.    
 In human PD, degradation of PDL collagen and alveolar bone is associated with 
persistent inflammation. Failure of the host immune response to resolve inflammatory 
mediators resulting in continued tissue damage is an essential determinant of PD 
outcomes. Our results suggest that intrinsic differences in ECM composition impact the 
host ability to respond, repair, and resolve PD. Additionally, our results implicate the 
potential predisposition of genetic mutations contributing to alterations in ECM 
assembly, collagen morphology, and alveolar bone biology, as major determinants of PD 
outcomes. Of future interest is investigating specific SPARC-expressing cell types 
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involved in exacerbating the PD phenotype, as well as the potential modulation of 
SPARC protein to alleviate chronic inflammatory states. Findings from future studies 
could highlight key molecular and/or genetic targets for diagnosis of clinical 





















Section 3. TG controls collagen cross-links in PD.  
Given the increased susceptibility to alveolar bone loss, deficits in collagen 
content, and aberrant changes in monocyte-derived cellular responses in the periodontium 
of SPARC-null mice, cellular mechanisms of collagen and ECM response in PD merited 
investigation. Insoluble collagen cross-links are a key aspect contributing to proper 
collagen assembly and morphology, incorporation into the ECM, and maintenance of 
tissue integrity. Data previously published by our laboratory have implicated the function 
of the cross-linking enzyme, TG, in fibrillar collagen assembly and regulation by SPARC 
in homeostatic PDL [66]. We report herein increases in immunostaining for TG2 and for 
N-ε-γ glutamyl lysine, the cross-link catalyzed by TG, in PD. PD in the absence of 
SPARC results in increased activity of TG2 in PDL, characterized by cross-link 
formation, over that of WT PDL. We demonstrate, for the first time, the expression of 
both TG2 and SPARC protein in human PDL fibroblasts from both healthy and diseased 
patients. Apparent increases in both TG2 and SPARC protein levels implicate 
mechanistic functions in human disease states. Inhibition of TG decreased alveolar bone 
volume fraction in WT mice (Fig. 30). Circulating TG, Factor XIII-A, is implicated in 
osteoblast differentiation [83]. Reductions in alveolar bone volume following treatment 
with a pan-TG inhibitor, are hypothetically due to inhibition of Factor XIII-A. Direct 
targeting of tissue TG2, would potentially alleviate the reported bone phenotype. 
Differences in PDL collagen morphology in PD, most notably the reductions in collagen 
fiber size and total amounts of collagen, were rescued by inhibition of TG activity in 
vivo. Visualization of native collagen morphology, by second-harmonic generation 
imaging, following disease and TG inhibition, exhibited restoration of PDL collagen 
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content and morphology viewed in 3-dimensions. The subsequent restoration of PDL 
fibrillar collagen morphology by inhibition of TG, functionally translated to increases in 
mechanical strength of PDL after disease. Our data provide evidence for a function of TG 
in fibrillar collagen regeneration in vivo following destruction mediated by PD. 
TG family members catalyze ECM cross-linking, a function that is implicated in 
stabilizing and cross-linking proteins. In addition to forming insoluble protein complexes, 
a critical function of TG in ECM collagen fiber assembly in vivo was established by our 
laboratory. Increased TG activity, in homeostatic PDL, resulted in the formation of 
smaller collagen fibrils and inhibition of TG activity increased total amounts of collagen, 
fibril diameter, and restored mechanical strength in both WT and SPARC-null mice [66]. 
Previous reports have shown that the expression and activity of TG is increased in 
various tissues during inflammatory disease states (neurodegenerative, autoimmune, 
intestinal inflammation, cancers) [163]. Increases in TG expression were reported in 
human patients experiencing gingival overgrowth [128, 129]. However, the mechanism 
of up-regulation and the physiological role for TG in the inflammatory process is poorly 
understood.  
There is evidence that TG2 prolongs the inflammatory phase of tissue healing. TG 
initiates a more aggressive inflammatory response by up-regulating TGF-β1 activation, 
enhancing phospholipase A2 activity through polyamination, and increasing macrophage 
phagocytosis [164]. Matarese et al. demonstrated increased TG2 mRNA levels in 
cultured hPDL cells from PD patients and showed the capability of TG2 to promote the 
activation of NF-κB by cross-linking it’s inhibitor: Iκ-βα. Reductions in TG activity in 
human THP-1-differentiated macrophages were concomitant with the loss in NF-κB 
	 127	
activation and reduction in RANKL expression. The authors concluded that TG2 initiates 
inflammation through the TG2/NF-κB interplay, which activates inflammatory cells by 
increasing RANKL expression in the PDL of periodontal diseased patients [134]. Similar 
to other matrix components that are induced following tissue injury, TG2 expression is 
increased through up-regulation of mRNA via cytokine induced transcriptional increases 
mediated by factors such as: TGF-β, TNF-α, IL-6 in tissues such as skin and liver [165-
167]. Of interest to our study are the implications of TG in remodeling of PDL collagen 
during PD. Our current results show that PD was associated with increased TG2 
expression and activity in PDL (Fig. 28), consistent with previous results in other tissues 
and inflammatory states. We hypothesize that the increase in TG2 expression and activity 
during PD is attributed to up-regulation of the promoter region by inflammatory 
cytokines.    
SPARC is an established substrate of TG, acting as a glutamine donor [80]. We 
report further increases by immunohistochemistry for N-ε-γ glutamyl lysine cross-link, 
following PD in SPARC-null over that observed in WT PDL (Fig. 28). Previously, our 
lab has shown no differences in baseline TG activity in PDL and liver from WT and 
SPARC-null mice by in vitro assays. Total protein extracted from SPARC-null PDL 
exhibited increased incorporation of a TG substrate (biotin cadaverine) versus WT [66]. 
These results suggest that SPARC does not directly inhibit the enzymatic activity of TGs, 
but instead alters the substrate specificity in the ECM. While TG expression is up-
regulated by inflammatory PD, the absence of SPARC increases the available TG 
substrates and allows for further TG-mediated cross-links compared to WT PD. 
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To further validate our hypothesis of TG activity contributing to collagen cross-
links during disease we conducted a series of experiments to inhibit the action of TG in 
vivo. Initially, in vivo TG inhibition in experimental PD was conducted only in WT mice 
to test validity as a therapeutic target in human disease. Inhibition of TG activity 
increased total amounts of PDL collagen and fiber thickness following PD in our WT 
mice (Fig. 31). We were able to confirm the 3D structure of native, fresh PDL collagen 
using SHG imaging (Fig. 32). The rescued collagen morphology following TG inhibition 
translated to functional increases in mechanical force required for molar extraction (Fig. 
34).  
Generally, increases in collagen cross-links have been associated with increases in 
mechanical strength and increases in tissue stiffness [168]. Hence, inhibition of TG-
dependent cross-linking associated with increased mechanical strength of a tissue might 
appear counterintuitive. However, increased collagen-cross links mediated by TG have 
been linked to reduced fiber thickness and reductions in mechanical strength of 
homeostatic PDL [66]. Therefore we conclude that smaller collagen fibers provide less 
mechanical strength regardless of increased cross-linking. The question of how collagen 
cross-links directly impact mechanical strength and stiffness is complex. For example, 
Fessel and colleagues recently reported that increases in tissue strength and stiffness 
frequently associated with increases in advanced glycation end-product (AGE) cross-
links did not impact stiffness of individual collagen fibrils in tendon. Differences in 
molecular sliding between supramolecular collagen structures were identified as an 
important factor in mediating the effects of AGE-modified collagen cross-links [169]. 
Willems et al. reported that a 300-fold increase in mature collagen pentosidine cross-links 
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in mandibular condyle cancellous bone did not alter bone tissue stiffness by 
nanoindentation [170]. Hence, the nature of the molecular basis by which TG activity 
determines collagen fiber thickness and mechanical strength will be insightful. Our 
results are the first reports of morphological and functional rescue of PDL collagen 
following disease.  
Somewhat surprisingly, TG inhibition increased alveolar bone loss in our model 
(Fig. 30B). Factor XIII-A, the plasma form of TG, is known to increase osteoblast 
differentiation in vitro cultures. Additionally, mice lacking TG2 and Factor XIII-A have a 
reduction in bone mass retention in long bones. Increased adipogenesis, 
osteoclastogenesis, and decreased integration of plasma fibronectin into bone matrix were 
characteristics of double-null skeletal phenotype. Up-regulation of TG1 expressed by 
monocytes and osteoclasts during osteoclastogenesis in double-null mice suggested a 
compensatory mechanism in regulating long bone mass [171]. Since BC is a pan-TG 
inhibitor, the reduction in bone volume fraction after BC injection would suggest similar 
roles for Factor XIII-A, TG2, and TG1 in the cranial skeleton. We hypothesize that 
specific targeting of tissue TG (TG2) and not Factor XIII-A, would restore the PDL 
collagen without decreasing alveolar bone volume since Factor XIII-A is thought to be 
the most important TG for bone turnover. TG2 specifically is implicated in cross-linking 
glial peptides of gluten and contributing to celiac disease [172]. Therefore, there are 
commercially available inhibitors of TG2. ZED1227, a peptidomimetic resembling an 
acyl-donor substrate with high affinity for the active site of TG2, is currently in clinical 
trials for therapeutic potential [173]. Perhaps the use of ZED1227 would be a better TG 
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inhibitor alternative to BC in restoring collagen content and morphology following PD 
without causing adverse affects in alveolar bone.         
Mechanisms underlying increased TG2 expression during induction of 
inflammation are attributed to up-regulated mRNA via the promoter region and cytokine 
response. The literature lacks reports of alterations in TG expression/activity in the 
proliferative and remodeling phases of inflammation. Results from inhibition of TG 
implicate TG in tissue ECM remodeling during inflammatory PD. We were able to show 
restoration of collagen morphology, thick fibers, and total content in diseased PDL, 
which translated to increases in mechanical strength of the tissues. Further investigation 
of TG2-specific targeting will give insight into the potential use of TG as a directed 
therapy in collagen biology in tissue remodeling following inflammatory destruction and 














There are several unanswered questions that should be addressed in the future. 
First, it is important to study the mechanism by which SPARC regulates TG’s cross-
linking activity in fibrillar collagen. Our central question focuses on the binding capacity 
of SPARC on collagen I to direct TG modification. The SPARC binding site on collagen 
is well established. Cyanogen bromide (CB) fragmentation of the collagen α1(I) strand 
did not result in significant changes in TG modification between WT and SPARC-null 
mice, implicating that the modifications of this strand were not dependent on SPARC 
binding to collagen (Bradshaw & Trombetta-eSilva, unpublished). However, CB 
fragmentation of the collagen α2(I) strand revealed apparent differences in TG 
modifications that did not correspond to mapped SPARC binding sites (Bradshaw & 
Trombetta-eSilva, unpublished). Future studies using mass spectroscopy to further 
analyze CB-generated collagen fragments will identify TG-modified residues. These 
experiments will facilitate the identification of specific glutamine residues involved in 
TG-mediated modifications and cross-links of collagen I. Directed inhibition of TG2 in 
SPARC-null compared to WT PDL will experimentally confirm the results from mass 
spectrometry.  
 TG catalyzes another reaction independent of collagen cross-linking that involves 
the covalent addition of free amines to glutamine residues. One such free amine present 
in vivo known to be modified by TG is serotonin [174]. Collagen modification by 
serotonin is unknown. Perhaps collagen is modified by serotonin and this modification is 
dependent on the presence or absence of SPARC. Since BC not only acts as a TG 
substrate but also as a free amine, there is potential for BC to block the serotonylation of 
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collagen in our model in vivo. It is widely known that patients taking selective serotonin 
reuptake inhibitors (SSRIs) have reduced bone turnover and impaired healing leading to 
more severe PD outcomes [175]. Mechanisms attributed to reductions in bone quality and 
increased fracture rates regarding the use of SSRIs are vastly unknown. Serotonin 
receptors and transporters have been identified on osteoblasts, osteoclasts, and osteocyte 
cell lines [176]. Interestingly, serotonin inhibits Factor XIII-A-mediated plasma 
fibronectin matrix assembly and crosslinking in osteoblast cultures by directly competing 
with FXIII-A transamidation reactions. In addition to a discontinuous pFN matrix, 
treatment of osteoblast cultures with serotonin resulted in impaired collagen deposition, 
mineralization, and lysyl oxidase activity [177]. Collagen and thrombin-activated 
platelets (COAT) are activated by TG2 and Factor XIII-A and link peripheral serotonin to 
procoagulant proteins enabling fibrinogen/thrombospondin bonding to the platelet 
surfaces [178]. Taken together, these data suggest that TG2/Factor XIII-A are important 
factors regulating serotonin binding to collagen. Future studies determining 
serotonylation of collagen and potential differences between WT and SPARC-null 
collagen modification will provide insight into TG-mediated activity, in addition to cross-
linking, contributing to changes in ECM. Results from these studies could be highly 
useful in studying ECM remodeling in vivo, particularly in PD.  
 Much attention has focused on macrophages in mediating the transition between 
inflammation and repair. Macrophages are known to express SPARC to aid in 
extravasation through endothelium during states of cardiac fibrosis and repair [152]. 
SPARC is thought to mediate cardiac inflammation by favoring an M1 macrophage 
phenotype while depressing markers of M2 macrophages [61]. Up-regulation of TG2 
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mRNA was correlated with increased levels of inflammatory markers IL-6, TNF-α, and 
HMGB-1 in THP-1-differentiated macrophages. TG2 inhibition reduced RANKL 
expression in macrophages [134]. Mice lacking TG2 exhibit macrophages deficient in 
clearance of apoptotic cells [179]. Our results herein indicate differences in PDL 
macrophage presence in WT and SPARC-null mice following ligature. Since our reported 
flow cytometric analysis indicated no differences in hematopoietic cell populations 
between WT and SPARC-null mice further investigation into ECM remodeling and 
macrophage response is warranted. Differences could be due to impaired macrophage 
recruitment in altered ECM environments of SPARC-null compared to WT PDL. Lineage 
tracing experiments using bone marrow transplants from GFP-labeled mice into SPARC-
null mice and SPARC-null bone marrow transplanted into WT mice will provide 
information on cell recruitment to site of disease or cell activation. If no differences are 
observed between SPARC-null and WT macrophage recruitment, it is possible that the 
phenotype of macrophages present are different. Perhaps SPARC-null macrophages in 
PDL favor a M1 phenotype, similar to what was observed in cardiac tissues, over that of 
an M2 phenotype. Analysis of secreted factors indicative of different macrophage 
populations will be insightful. In vitro bone marrow-derived macrophage polarization 
conducted using bone marrow isolates from WT and SPARC-null following PD 
induction could indicate differences in preferential macrophage populations between 
mice in response to disease. To further assess how SPARC and TG2 affect the 
inflammatory response, cultured macrophages could be stimulated with SPARC and TG2 




 Experiments reported in this thesis have shown that both SPARC and the N-
propeptide of collagen I are critical for collagen homeostasis in healthy PDL. This is the 
first report of a functional role of the N-propeptide, in isolation, in collagen cellularity 
and PDL tissue integrity. In disease, the absence of SPARC leads to increased severity of 
alveolar bone loss and PDL collagen degradation. Data described herein demonstrate, for 
the first time that inhibition of TG is associated with change in collagen fiber morphology 
and likely contributes to PD severity. Furthermore, significant changes mediated by PD 
in collagen fiber content, morphology, and mechanical functionality in WT PDL were 
restored by inhibition of TG activity in vivo. Thus, we present evidence in support of a 
critical role of both SPARC and TG in the regulation of collagen I fiber assembly. These 
results have broad implications for strategies for, not only PDL collagen regeneration, but 
also broadly for collagen rich-tissues following inflammatory and fibrotic disease states. 
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